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A B S T R A C T
Background
Malaria is an important cause of illness and death across endemic regions. Considerable success against malaria has been achieved within
the past decade mainly through long-lasting insecticide-treated nets (LLINs). However, elimination of the disease is proving difficult
as current control methods do not protect against mosquitoes biting outdoors and when people are active. Repellents may provide a
personal protection solution during these times.
Objectives
To assess the impact of topical repellents, insecticide-treated clothing, and spatial repellents on malaria transmission.
Search methods
We searched the following databases up to 26 June 2017: the Cochrane Infectious Diseases Group Specialized Register; the Central
Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; Embase; US AFPMB; CAB Abstracts;
and LILACS. We also searched trial registration platforms and conference proceedings; and contacted organizations and companies for
ongoing and unpublished trials.
Selection criteria
We included randomized controlled trials (RCTs) and cluster-randomized controlled trials of topical repellents proven to repel
mosquitoes; permethrin-treated clothing; and spatial repellents such as mosquito coils. We included trials that investigated the use of
repellents with or without LLINs, referred to as insecticide-treated nets.
Data collection and analysis
Two review authors independently reviewed trials for inclusion, extracted the data, and assessed the risk of bias. A third review author
resolved any discrepancies. We analysed data by conducting meta-analysis and stratified by whether the trials had included LLINs.
We combined results from cRCTs with individually RCTs by adjusting for clustering and presented results using forest plots. We used
GRADE to assess the certainty of the evidence.
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Main results
Eight cRCTs and two RCTs met the inclusion criteria. Six trials investigated topical repellents, two trials investigated insecticide-treated
clothing, and two trials investigated spatial repellents.
Topical repellents
Six RCTS, five of them cluster-randomized, investigated topical repellents involving residents of malaria-endemic regions. Four trials
used topical repellents in combination with nets, but two trials undertaken in displaced populations used topical repellents alone.
It is unclear if topical repellents can prevent clinical malaria (RR 0.65, 95% CI 0.4 to 1.07, very low certainty evidence) or malaria
infection (RR 0.84, 95% CI 0.64 to 1.12, low-certainty evidence) caused by P. falciparum. It is also unclear if there is any protection
against clinical cases of P. vivax (RR 1.32, 95% CI 0.99 to 1.76, low-certainty evidence) or incidence of infections (RR 1.07, 95% CI
0.80 to 1.41, low-certainty evidence). Subgroup analysis of trials including insecticide-treated nets did not show a protective effect of
topical repellents against malaria. Only two studies did not include insecticide-treated nets, and they measured different outcomes; one
reported a protective effect against clinical cases of P. falciparum (RR 0.40, 95% CI 0.23 to 0.71); but the other study measured no
protective effect against malaria infection incidence caused by either P. falciparum or P. vivax.
Insecticide-treated clothing
Insecticide-treated clothing were investigated in trials conducted in refugee camps in Pakistan and amongst military based in the
Colombian Amazon. Neither study provided participants with insecticide-treated nets. In the absence of nets, treated clothing may
reduce the incidence of clinical malaria caused by P. falciparum by approximately 50% (RR 0.49, 95% CI 0.29 to 0.83, low-certainty
evidence) and P. vivax (RR 0.64, 95% CI 0.40 to 1.01, low-certainty evidence).
Spatial repellents
Two cluster-randomized RCTs investigated mosquito coils for malaria prevention. We do not know the effect of spatial repellents on
malaria prevention (RR 0.24, 95% CI 0.03 to 1.72, very low certainty evidence). There was large heterogeneity between studies and one
study had high risk of bias.
Authors’ conclusions
There is insufficient evidence to conclude topical or spatial repellents can prevent malaria. There is a need for better designed trials
to generate higher certainty of evidence before well-informed recommendations can be made. Adherence to daily compliance remains
a major limitation. Insecticide-treated clothing may reduce risk of malaria infection in the absence of insecticide-treated nets; further
studies on insecticide-treated clothing in the general population should be done to broaden the applicability of the results.
P L A I N L A N G U A G E S U M M A R Y
Mosquito repellents for malaria prevention
What was the aim of this review?
The aim of this Cochrane Review was to find out if mosquito repellents - topical repellents (applied to the skin); insecticide-treated
clothing; or spatial repellents such as mosquito coils - can prevent malaria. We collected and analysed the results of all relevant studies
to answer this question and found data from ten trials: six on topical repellents, two on insecticide-treated clothing, and two on spatial
repellents.
Key messages
We do not know if the use of repellent lotions or burning of mosquito coils can provide protection from malaria to communities living
in endemic regions. In situations where long-lasting insecticide-treated bed nets (LLINs) cannot be rolled out, such as after a natural
disaster or amongst displaced populations, the use of insecticide-treated clothing may reduce the risk of malaria infection by 50%. Most
studies included in our analysis were poorly designed and had high risk of bias. In order to draw well-informed conclusions, further
high-quality studies must be conducted to improve the certainty of the evidence. However, it is questionable if topical repellents can be
used for malaria prevention in the general population as daily compliance and poor standardization (amount of repellent used, surface
area applied, time of application, and period between repeated applications) are major limitations of this intervention.
What was studied in this review
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Mosquito repellents provide protection from mosquito bites. There are three different types of repellents: topical repellents, which can
be applied on the skin; insecticide-treated clothing, through impregnation of clothing with repellent compounds; and spatial repellents,
such as mosquito coils. Malaria has decreased in many countries because people have been given highly effective LLINs. However
people are still being bitten before they go to bed. There is a need to find a way to offer protection from malaria during these hours.
Mosquito repellents may address this gap.
What are the main results of the review?
A total of six trials investigated the use of topical repellents for malaria prevention. The trials took place in different malaria-endemic
regions across South America, Asia, and sub-Saharan Africa. The topical repellents tested included lotions, treated soap, and local
cosmetics. We analysed the studies in groups according to LLIN inclusion. Most studies rolled out LLINs to the population and
investigated topical repellents as a complementary intervention to the treated bed-nets. The poor design of the included studies provided
low to very low certainty evidence, consequently we do not know if there is a benefit of using topical repellents in addition to LLINs to
prevent malaria. The compliance of participants to adhere to the daily application of repellents remains a challenge to further research.
Insecticide-treated clothing was investigated in two trials conducted with refugees in Pakistan and military deployed in the Amazon;
neither study rolled out or reported the use of bed-nets. In the absence of LLINs, there is some evidence that insecticide-treated clothing
may reduce the risk of malaria infection by 50%. Given that the findings relate to special populations living in particularly harsh
conditions it is unclear if the results are applicable to the general population. Further studies involving civilian populations should be
done to improve the certainty of these findings.
Two studies investigated the practice of burning mosquito coils to reduce malaria infections. One study was conducted in China and
the other in Indonesia. The study designs were substantially different and one study had high risk of bias leading to very low certainty
evidence. We do not know if mosquito coils offer protection against malaria. The findings underline the need for further research.
How up to date is this review?
The review authors searched for studies that had been published up to 26 June 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical repellents compared to placebo or no treatment for malaria prevention
Patient or population: malaria prevent ion
Setting: malaria-endemic regions
Intervention: topical repellents
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Placebo or no
treatment
Risk with Topical re-
pellents
Clinical malaria: P. falci-
parum
39 per 1000 25 per 1000
(15 to 41)
RR 0.65
(0.40 to 1.07)
4450
(3 studies)
⊕©©©
VERY LOW1,2,3
Due to risk of bias, in-
consistency and impre-
cision
We do not know if top-
ical repellents have an
ef fect on malaria cases
caused by P. falciparum.
We have very lit t le con-
f idence in the ef fect es-
t imate. The true ef fect
is likely to be substan-
t ially dif f erent f rom the
est imate of ef fect
Parasitaemia: P. falci-
parum
15 per 1000 12 per 1000
(9 to 17)
RR 0.84
(0.64 to 1.12)
13,310
(4 studies)
⊕⊕©©
LOW4,5
Due to risk of bias and
imprecision
Topical repellents may
or may not have
a protect ive ef fect
against P. falciparum
parasitaemia. Our con-
f idence in the ef fect es-
t imate is lim ited. The
true ef fect may be sub-
stant ially dif f erent f rom
the est imation of the ef -
fect
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Clinical malaria: P. vivax 36 per 1000 48 per 1000
(36 to 64)
RR 1.32
(0.99 to 1.76)
3996
(2 studies)
⊕⊕©©
LOW6,7
Due to risk of bias and
imprecision
Topical repellents may
increase the number of
clinical cases caused
by P. vivax. Our conf i-
dence in the ef fect es-
t imate is lim ited. The
true ef fect may be sub-
stant ially dif f erent f rom
the est imation of the ef -
fect
Parasitaemia: P. vivax 18 per 1000 19 per 1000
(14 to 25)
RR 1.07
(0.80 to 1.41)
9434
(3 studies)
⊕⊕©©
LOW7,8
Due to risk of bias and
imprecision
Topical repellents may
or may not have a pro-
tect ive ef fect against P.
vivax parasitaemia Our
conf idence in the ef fect
est imation is lim ited.
The true ef fect may
be substant ially dif f er-
ent f rom the est imation
of the ef fect
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for risk of bias: Sangoro 2014a used alternate allocat ion and reported a baseline imbalance; random
sequence generat ion and allocat ion concealment were not described by Rowland 2004; and Sluydts 2016 did not have a
placebo so the intervent ion was not blinded.
2Downgraded by 1 because of the large heterogeneity between the 3 trials. The I² stat ist ic, which quant if ies the proport ion
of the variat ion in the point est imates due to among-study dif ferences, was considered substant ial at 50%. The subgroup
analysis to some extent explained the heterogeneity but we do not believe that there is enough evidence to suggest there is a5
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t rue subgroup ef fect given that there is no heterogeneity in the outcome parasitaemia caused by P. falciparum where studies
with and without LLINs were also analysed.
3Downgraded by 1 for imprecision because the sample size is too small, the CIs are wide, the pooled ef fect (0.40 to 1.07)
overlaps a risk rat io (RR) of 1.0 (no ef fect) and presents an est imate of ef fect ranging between benef icial and harmful.
4Downgraded by 1 for risk of bias: Hill 2007 used alternate allocat ion and reported a baseline imbalance; random sequence
generat ion and allocat ion concealment were not described by McGready 2001.
5Downgraded by 1 for imprecision because the sample size is too small, the CIs are very wide, the pooled ef fect (0.62 to 1.12)
overlaps a risk rat io (RR) of 1.0 (no ef fect) and presents an est imate of ef fect ranging between benef icial and harmful.
6Downgraded by 1 for risk of bias: random sequence generat ion and allocat ion concealment were not described by Rowland
2004; Sluydts 2016 was not placebo-controlled and intervent ion was not blinded.
7Downgraded by 1 for imprecision because the CIs are very wide, the pooled ef fect (0.80 to 1.41) overlaps a risk rat io (RR) of
1.0 (no ef fect) and presents an est imate of ef fect ranging between benef icial and harmful.
8Downgraded by 1 for risk of bias: random sequence generat ion and allocat ion concealment were not described by McGready
2001.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Malaria is caused by protozoan parasites of the genus Plasmodium.
The most severe form of the disease is caused by Plasmodium fal-
ciparum. Other Plasmodium species known to cause milder cases
of malaria include Plasmodium vivax, Plasmodium ovale, and Plas-
modiummalariae. The parasites are transmitted to people through
the bite of an infected Anophelesmosquito. Malaria is widespread
in tropical and subtropical regions and is considered endemic in 91
countries worldwide (WHO 2017). Symptoms of malaria include
fever, chills, headache, and vomiting, and usually appear between
10 to 15 days after the bite of an infected mosquito. If left un-
treated, the person may develop severe complications and malaria
can quickly become life-threatening by disrupting the blood sup-
ply to vital organs. Diagnosis is done through identification of the
Plasmodium parasite in the patient’s bloodstream, usually by mi-
croscopic examination of a blood slide or malaria rapid diagnostic
tests (mRDTs).
In the past decade, great advances have been made in the fight
against malaria. From 2000 to 2016 global incidence of malaria
fell by 40% and related mortality by 62% (WHO 2017). This is
due to massive scale-up of vector control interventions using long-
lasting insecticide-treated bed nets (LLINs) and indoor residual
spraying (IRS), as well as the introduction of mRDTs for bet-
ter malaria diagnosis and use of highly effective artemisinin-based
combination therapies (ACTs). Despite these developments, an
estimated three billion people living in 91 countries are still at risk
of contracting malaria and 1200 children under five years old die
every day in malaria-endemic regions (WHO 2017). The World
Health Organization’s (WHO) Global Technical Strategy (GTS)
aims to reduce global malaria incidence and mortality rates by
90% by 2030, with a milestone of at least 40% reduction by 2020.
The GTS also set targets to eliminate the disease in at least 10
countries by 2020 and 35 countries by 2030. While the vector
control component of most national malaria control programmes
concentrates on distribution of LLINs and IRS, there is substantial
malaria transmission within and outside Africa at times when peo-
ple are outdoors (Durnez 2013). Recent estimates are that 10% of
global malaria burden occurs outside Africa, with approximately
58% of P. vivax cases occurring in the WHO South-East Asia
Region (WHO 2017), where vectors are primarily early evening
feeders (Sinka 2010; Sinka 2011). In order to achieve sustained
malaria control and move towards malaria elimination, new tools
will be required to interrupt transmission in environments where
existing tools are not completely effective (malERA 2011). Resid-
ual malaria transmission is maintained by the presence of asymp-
tomatic carriers, the significant number of non-compliant LLIN
users, early evening outdoor-feeding Anopheles mosquitoes, and
the spread of drug and insecticide resistance (White 2014). As well
as preventing early evening bites, mosquito repellents may be suit-
able for people who have a high occupational risk of contracting
malaria, such as: those working at night particularly inmining; sol-
diers; people in close contact with forest ecosystems; and migrants
(Sangoro 2014b). It is well known that these high-risk individuals
’re-seed’ malaria in areas where vector control activities are carried
out (Tatem 2010). With the impetus for malaria eradication of
the past decade and the realization that the existing control tools
alone cannot achieve this, mosquito repellents are increasingly be-
ing considered as supplementary tools in some malaria-endemic
settings (Sturrock 2013).
Description of the intervention
Personal protection has been used for centuries to prevent
mosquito bites (Herodotus 1996). Historically, people burned re-
pellent plants and applied essential oils directly to their skin or
clothing. In recent times, manufacturers have developed more ef-
fective products that have largely replaced traditional methods.
These products includemosquito coils, long-lasting formulated re-
pellent lotions, and insecticide treatments for clothing. Mosquito
repellents are currently recommended by the WHO as the first-
line malaria-prevention tool for travellers (WHO 2012), and they
are commonly used by expatriates in tropical developing countries.
There are three main interventions that help prevent mosquito
bites:
• applying topical repellents directly to the skin;
• wearing insecticide-treated clothing (ITC);
• using spatial repellents.
Themode of action of these three interventions on themosquito is
not the same; however they all result in preventing mosquito bites
outside sleeping hours and so potentially reduce transmission of
Plasmodium parasites from infected mosquitoes to humans.
Topical repellents
Topical repellents may contain a wide range of active ingredi-
ents and are available in various formulations in lotions, gels,
roll-ons, and on wipes. Repellents interfere with mosquitoes’ ol-
factory reception, affecting their ability to locate and feed on
a human host. Approved active ingredients for mosquito-borne
disease prevention are DEET (chemical name: N,N-diethyl-m-
toluamide or N,N-diethyl-3-methyl-benzamide); icaridin (KBR
3023 [Bayrepel] and picaridin inside the USA; chemical name:
2-2-hydroxyethyl-1-piperidinecarboxylic acid 1-methylpropyl es-
ter); PMD (para-methane-3,8-diol); and IR3535 (chemical name:
3-[N-butyl-N-acetyl]-aminopropionic acid, ethyl ester) (CDC
2014;WHO2012). TheEnvironmental ProtectionAgency (EPA)
estimates that approximately 200million people useDEETworld-
wide every year (WHOPES 1998).
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ITC
ITC is widely used by military personnel to protect against vector-
borne diseases and biting nuisance (Kitchen 2009). The synthetic
pyrethroid permethrin (2 g/m²) is used most commonly for treat-
ment of clothing. Permethrin is approved by the WHO for this
purpose because of its low dermal absorption, low mammalian
toxicity, lack of odour and minimal irritation (WHOPES 2006).
The mode of action of ITC is through contact irritancy, whereby
mosquitoes make oriented movement away from the person after
physical contact with the treated clothing surface; it also affects
mosquitoes’ feeding response. Both of these modes of action result
in a reduction in mosquito bites to the person using the treated
material.
Spatial repellents
Spatial repellents disperse active ingredients into the surround-
ing air that interfere with the mosquito’s ability to find a host,
thus preventing mosquitoes from taking a blood meal. They may
interfere with host detection; or cause insects to fly in an undi-
rected manner until they eventually move away from the source
of repellent vapour (excito-repellency). Spatial repellents create a
protective area within a given radius and can be used to protect
more than one person at the same time. Dispersal of the active
ingredient can be done in two ways:
• through heat, for example mosquito coils and electric
emanators; or
• through evaporation, for example passive emanators made
of paper or agarose gel.
The most popular format is themosquito coil and an estimated 45
to 50 billion mosquito coils are used annually by approximately
two billion people worldwide, mainly in Southeast Asia (Zhang
2010). Mosquito coils are made from a mixture of inert ingredi-
ents, such as sawdust or coconut husks, and pigment. The coils
burn at a low temperature dispersing the active ingredient, usually
a volatile pyrethroid with a quick knock-down action (for exam-
ple, pyrethrin, D-allethrin, transfluthrin, or metofluthrin). The
smoke produced by the burning of mosquito coils can cause in-
door air pollution.
Electric emanators consist of an electrical heating agent that va-
porizes insecticide that has been impregnated into a pad or wick.
These produce no smoke but require a source of electricity, which
is not available in a large proportion of homes in malaria-endemic
countries.
Passive emanators do not require a source of heat or combustion.
They have a large surface area which allows the passive dispersal
of the volatile active ingredient into the air by evaporation. The
chosen active ingredients are predominantly less polar compounds
that are easily volatilized: examples include volatile pyrethroids
such as metofluthrin and transfluthrin.
How the intervention might work
During the first Global Malaria Eradication Campaign the con-
cept of vectorial capacity was developed and validated to mathe-
matically evaluate the impact of mosquito-control interventions
on malaria transmission using several measurable field parameters
(Garrett-Jones 1964). Vectorial capacity is defined as: “the daily
rate at which future inoculations of a parasite arise from a currently
infective case, provided that all female vectors biting that case
become infected” (Garrett-Jones 1964). The original validation
demonstrated that by reducing man vector contact (mosquito
bites) by 50% there was a consequent 75% reduction in vectorial
capacity. Man vector contact can be reduced by using repellents.
Mosquitoes will be repelled or disabled from feeding on a person
while being exposed to the repellent. These personal protective
measures can be used at any time or location, and so are suitable for
controlling mosquitoes biting outdoors and during early evening
hours before people go to bed. Repellents might also protect indi-
viduals from other mosquito-borne diseases such as dengue, Zika,
and chikungunya.
Why it is important to do this review
The wide distribution of LLINs in malaria-endemic countries
has resulted in a considerable reduction of malaria incidence and
prevalence throughout affected areas (WHO 2017). However
residual malaria transmission, defined as the malaria transmission
occurring despite universal coverage with effective IRS or LLINs,
requires other vector control interventions, particularly outdoors
and outside sleeping hours. It is estimated that in South Amer-
ica and Southeast Asia 80% of malaria transmission occurs be-
fore sleeping hours. Even in Africa, where Anopheles mosquitoes
are traditionally late feeders, up to 20% of malaria transmission
takes place during early evening and earlymorning hours (Sangoro
2014b). During this time the only available means of protection
are repellents or ITC, thus these interventions might have the
potential to reduce residual transmission. This Cochrane Review
aimed to measure the effectiveness of these interventions - either
alone or when combined with LLINs - in reducing the incidence
of malaria, to facilitate decision makers considering the inclusion
of repellents in national malaria control programmes. In addition,
we believe that this review may be helpful in the pursuit of Goal
3 of the United Nations Sustainable Development Goals (SDGs),
to ensure healthy lives and promote well-being for all at all ages. The
specific SDG 3 targets that this review addresses include:
• by 2030, reduce the global maternal mortality ratio to less
than 70 per 100,000 live births: pregnant women are more
attractive to mosquitoes and therefore at a higher risk of
infection than when the same women are not pregnant. In
addition, pregnant women are particularly susceptible to
complications of malaria. Modern repellents are safe to use
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among pregnant women and therefore have the potential to
confer protection to a high-risk group;
• by 2030, end preventable deaths of newborns and children
under five years of age, with all countries aiming to reduce
neonatal mortality to at least as low as 12 per 1000 live births
and under-five mortality to at least as low as 25 per 1000 live
births. Reducing the number of mosquito bites a child receives
has been shown to lower the morbidity from malaria (Snow
1998). Repellents may also reduce other vector-borne diseases as
the most widely used repellents are broad spectrum and prevent
bites from a range of disease vectors;
• by 2030, end the epidemics of AIDS, tuberculosis, malaria,
and neglected tropical diseases, and combat hepatitis, water-
borne diseases, and other communicable diseases: by directly
reducing the human-vector biting rate and reducing malaria
transmission.
O B J E C T I V E S
To assess the impact of topical repellents, insecticide-treated cloth-
ing (ITC), and spatial repellents on malaria transmission.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomized controlled trials (RCTs) or cluster
randomized controlled trials (cRCTs) with more than two units
of randomization.
Types of participants
We included all adults and children living in malaria-endemic
areas.
Types of interventions
We included trials with or without LLINs in both trial arms.
Intervention
• ITC impregnated with permethrin; or
• topical repellents including DEET, icaridin, picardin,
IR3535, and PMD; or
• spatial repellents including transfluthrin coils, metofluthrin
coils, D-allethrin coils, pyrethrin coils, metofluthrin emanators,
and transfluthrin emanators.
Control
Individuals given a placebo or no treatment.
Types of outcome measures
Primary outcomes
• Clinical malaria: confirmed through blood smears or rapid
diagnostic tests (P. falciparum or P. vivax);
• malaria parasitaemia (malaria infection incidence):
confirmed through thick or thin blood smears, mRDTs, or
polymerase chain reaction (PCR) (P. falciparum or P. vivax).
Secondary outcomes
• Anaemia (haemoglobin < 10 g/dL);
• time to first infection (days);
• all-cause fever;
• adherence to regular usage of the intervention measured
through spot-checking per period of time;
• reduction in mosquitoes attempting to feed on humans;
• recorded adverse events such as skin irritation, irritation of
upper airways, nausea, and headache.
Search methods for identification of studies
We identified all relevant trials regardless of language or publi-
cation status (published, unpublished, in press, and in progress)
(Lefebvre 2011).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register (up to 23 June 2017); MED-
LINE (PubMed, 1966 to 26 June 2017); Embase (OVID, 1974 to
26 June 2017); CAB Abstracts (Web of Science, 1910 to 26 June
2017), and LILACS (1982 to 26 June 2017). We also searched
the United States Armed Forces Pesticide Management Board
website (US AFPMB; www.acq.osd.mil/eie/afpmb) on 12 Au-
gust 2016; the WHO International Clinical Trials Registry Plat-
form (ICTRP; www.who.int/trialsearch); and ClinicalTrials.gov
on 26 June 2017, using ’randomised controlled Trial’, ’con-
trolled clinical trial’, ’mosquito*’, ’Anopheles’, ’malaria’, ’DEET’,
’PMD’, ’IR3535’, ’Icaridin’, ’Metofluthrin’, ’Transfluthrin’, ’va-
porizer mat*’, ’electric emanator’, insecticide treated clothing’,
’ITC’, ’personal protection’, and ’repellen*’ as search terms.
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Searching other resources
Conference proceedings
We searched the following conference proceedings of the relevant
abstracts:
• MIM conference abstract booklets (2008 to present);
• Annual ASTMH conference (2008 to present);
• Entomological Society of America (2008 to present);
• Society of Vector Ecology of America (2008 to present).
Organizations and pharmaceutical companies
We contacted organizations (including the WHO, Centers for
Disease Control and Prevention (CDC), United States Depart-
ment of Agriculture (USDA), United States Agency for Interna-
tional Development (USAID), US AFPMB, and Deployed War
Fighter Protection Program (DWFP)) and chemical companies
(including Bayer, Sumitomo, Vestergaard-Frandsen, BASF, SC
Johnson, Insect Shield, Mosiguard, Sara Lee, and Syngenta) for
ongoing and unpublished trials.
Reference lists
We also checked the reference lists of all included trials for further
relevant studies.
Data collection and analysis
Selection of studies
Two review authors (MM and MK) independently assessed the
titles and abstracts of trials identified by the searches. The same two
review authors assessed full-text copies of potentially relevant trials
for inclusion using an eligibility form based on inclusion criteria.
They compared included trials, and resolved any disagreements
by discussion and consensus, with arbitration when necessary by
one or two more review authors (SJM and CL). We ensured that
multiple publications of the same trial were only included once.We
listed excluded studies, together with their reasons for exclusion,
in table format.
Data extraction and management
Two review authors (MMandMV) independently extracted infor-
mation from the trials using pre-piloted, electronic data extraction
forms. Differences in extracted data were discussed between both
authors until a consensus was reached. In cases where a consensus
could not be reached, further discussions were held involving one
or two more authors (SJM and CL). In cases where missing data
were identified, we contacted the original trial author(s) for clari-
fication.
We extracted data on the following:
• trial design: type of trial; method of participant selection;
unit of randomization (for RCTs); adjustment for clustering for
cRCTs; sample size; method of blinding of participants and
personnel; diagnostic method; primary vector; vector biting
time; malaria endemicity; Plasmodium species;
• participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up;
• intervention: description of intervention; co-interventions;
description of controls; time of follow-up; passive or active case
detection; compliance;
• outcomes: definition of outcome; number of events;
number of participants; power; unit of analysis; incomplete
outcomes/missing data.
For dichotomous outcomes, we extracted the number of patients
experiencing each outcome and the number of patients in each
treatment group. For continuous outcomes, we extracted themean
and a measure of variance (standard error) for each treatment
group.
For cRCTs we recorded the number of clusters randomized; num-
ber of clusters analysed; measure of effect (such as risk ratio, odds
ratio, or mean difference) with confidence intervals (CIs) or stan-
dard deviations; number of participants; and the intra-cluster cor-
relation coefficient (ICC) value.
Assessment of risk of bias in included studies
Two review authors (MM andMK) independently assessed risk of
bias for each included trial using the Cochrane’s ’Risk of bias’ tool
(Higgins 2011). Any discrepancies were resolved through discus-
sion or by consulting one or two more review authors (SJM and
CL). We classified judgements of risk of bias as either ’low’, ’high’
or ’unclear’, using summary graphs (’Risk of bias’ summary and
’Risk of bias’ graph) to display results.
We assessed each of the following components for each included
RCT randomized by the individual and by cluster.
Sequence generation
Wedescribed themethods used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it produced
comparable groups. We regarded a trial as having a low risk of se-
lection bias if the sequence generationwas truly random (for exam-
ple computer-generated table of random numbers, tossing a coin);
a high risk of bias if sequence generation was non-random (for
example alternate randomization, randomization by birth date);
or an unclear risk of bias if the randomization process was not
clearly described.
Balance
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We assessed if both arms of the trial were equally balanced at base-
line using criteria including age, gender,malaria indicators, socioe-
conomic status, housing, use of other interventions, knowledge
about malaria transmission, and occupation.
Allocation concealment
We described the method used to conceal allocation to treatment
groups before assignment.We regarded trials as having a low risk of
selection bias if allocation was truly concealed (for example central
allocation of participants; use of sequentially numbered, opaque,
sealed envelopes; lottery system); a high risk of bias if the alloca-
tion process was not concealed (for example open randomization,
unsealed or non-opaque envelopes); or an unclear risk of bias if
the process of concealing allocation was not described sufficiently
to make a judgement.
Blinding of participants and personnel
Wedescribed whether blinding was present, who was blinded, and
the methods used to blind trial participants and personnel. We
regarded a trial as having a low risk of performance bias if blinding
was present, or if the absence of blinding was unlikely to affect
the outcomes; a high risk of bias if blinding was absent and likely
to affect the results; or an unclear risk of bias if blinding was not
clearly described.
Blinding of outcome assessors
Regarding blinding of outcome assessors: we described whether
blinding of outcome assessors was present, and how they were
blinded. We regarded a trial as having a low risk of detection bias
if they were blinded to knowledge about which intervention the
participants received; a high risk of bias if blinding was absent; or
an unclear risk if blinding was not clearly described.
Incomplete outcome data
We described the percentage and proportion of patients who were
lost to follow-up; reasons for attrition; and whether attrition was
balanced across groups or related to outcomes. We regarded trials
as having a low risk of attrition bias if there were no missing data
or if missing data were balanced across groups or clusters; high
risk of bias if there were missing data or if missing data were more
prevalent in one of the groups; or unclear risk of bias if it is unclear
whether outcome data are missing.
Selective outcome reporting
Werecorded any discrepancies between the pre-specified outcomes
in the Methods section and the outcomes reported, and identified
outcomes that were measured but not reported on. We regarded
a trial as having low risk of reporting bias if it was evident that all
pre-specified outcomes were reported on; high risk of bias if it was
evident that not all pre-specified outcomes were reported on; and
unclear risk of bias if it was unclear whether all outcomes were
reported on.
Incorrect analysis
We described whether the analysis was appropriate; whether an
analysis plan was followed; and if it was adjusted for clustering.
Other bias
We described any important feature of included trials that could
have affected the result.
In addition to the above, we assessed the following for each in-
cluded cRCT.
Recruitment bias
Regarding recruitment bias, we described whether participants
were recruited before or after randomization of clusters. We re-
garded trials as having low risk of recruitment bias if participants
were recruited before randomization of clusters; high risk of bias
if they were recruited after randomization; and unclear risk of bias
if information about the timing of recruitment was unclear.
Loss of clusters
We described the number of clusters lost, as well as the reasons for
attrition.
Compatibility with RCTs randomized by individuals
We noted whether the intervention effects may be systematically
different from individually RCTs - that is, whether it was likely
that the effect size was over- or underestimated.
Measures of treatment effect
We compared intervention and control data using risk ratios. All
results were presented with their associated 95% confidence inter-
vals (95% CIs). Data regarding reduction in mosquito bites was
compared using mean difference and standard deviation.
Unit of analysis issues
We combined results from cRCTs with individually RCTs if they
had adjusted for clustering in their analysis and presented results
using forest plots. If there was no adjustment for clustering in
RCTs, we adjusted data before combining it with data from in-
dividually RCTs. We adjusted the data by multiplying standard
errors by the square root of the design effect (Higgins 2011). If
the trial did not report the ICC value, we estimated the ICC from
a similar trial, or by searching external sources for example ICCs.
Regarding studies which measured malaria transmission through
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active case detection and reported results from multiple cross-sec-
tional studies, only data from the last cross-sectional study was
included in the meta-analysis.
Dealing with missing data
In case of missing data, we applied available-case analysis, only
including data on the known results. The denominator used was
the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we carried
out analyses on an intention-to-treat (ITT) basis. We included all
participants randomized to each group in the analyses and analysed
participants in the group to which they were randomized.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs and assessed statis-
tical heterogeneity in each meta-analysis using the I² and Chi²
statistics. We regarded heterogeneity as moderate if I² values are
between 30% to 60%; substantial if they are between 59% to
90%; and considerable if they are between 75% to 100%. We re-
garded a Chi² test statistic with a P value less than or equal to 0.10
as indicative of statistically significant heterogeneity. We explored
clinical and methodological heterogeneity through consideration
of the trial populations, methods and interventions, and by visu-
alization of trial results.
Assessment of reporting biases
In cases where 10 or more trials were included in each meta-
analysis, we investigated reporting biases (such as publication bias)
using funnel plots. We assessed funnel plot asymmetry visually,
and used formal tests for funnel plot asymmetry (Harbord 2006).
We explored reasons for asymmetry.
Data synthesis
We grouped trials and analysed by these interventions:
• topical repellents;
• ITC;
• spatial repellents.
Within each group, we stratified by whether LLINs were included
in both intervention and control groups.
We analysed data using Review Manager 5 (RevMan 5) software
(Review Manager 2014). We used fixed-effect meta-analysis to
combine data when heterogeneity was absent. If considerable het-
erogeneity was present, we combined data using random-effects
meta-analysis and reported an average treatment effect. We de-
cided whether to use fixed-effect or random-effects meta-analysis
based on the consideration of clinical and methodological hetero-
geneity between trials, as described previously.
Certainty of the evidence
We rated the certainty of the evidence using theGRADE approach
(Guyatt 2011). Each important outcome was rated as follows, as
described by Balshem 2011:
• high: we are very confident that the true effect lies close to
that of the estimate of the effect;
• moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect;
• low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect;
• very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high certainty evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect; a dose-
response effect; and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect
if no effect was observed (Balshem 2011). We summarized our
findings in a ’Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We explored reasons for substantial heterogeneity using subgroup
analysis. We subgrouped trial data on clinical malaria and malaria
parasitaemia based on whether the study had investigated the re-
pellent intervention in combination with insecticide-treated bed
nets. We assessed differences between subgroups using the Chi²
test, with a P value less than or equal to 0.05 indicating statistically
significant differences between subgroups.
Sensitivity analysis
We performed sensitivity analysis on the primary outcome to see
the effect of exclusion of trials at high risk of bias (for improper
randomization methods and allocation concealment) on overall
results. The same analysis was done to investigate whether the ex-
clusion of being placebo-controlled had an effect. If the ICC value
was estimated, we carried out sensitivity analyses to investigate the
impact of varying the ICC on results from the meta-analysis.
We conducted three sensitivity analyses to test the robustness of
our results:
• sensitivity analysis 1: excluded trials at high risk of bias for
improper randomization and allocation concealment;
• sensitivity analysis 2: excluded non-placebo controlled trials;
• sensitivity analysis 3: varied the estimated ICC for trials
that did not report ICC.
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R E S U L T S
Description of studies
Results of the search
We searched the available literature up to 26 June 2017 and iden-
tified 440 citations from the electronic database searches and three
from other sources. We identified two duplicates. We screened
441 articles by title and abstract. We selected abstracts that po-
tentially matched our inclusion criteria, and also articles where it
was unclear whether or not they fulfilled the inclusion criteria, for
full-text assessment. We excluded 425 articles and identified 16
full-text articles for further assessment. After full-text assessment
of these articles, we excluded and listed six articles; and we gave
reasons for exclusion in the Characteristics of excluded studies ta-
ble. Ten articles met the inclusion criteria and were included in
the qualitative and quantitative synthesis. We have illustrated the
study selection process in Figure 1.
Figure 1. Study flow diagram.
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Included studies
Two RCTs, McGready 2001 and Soto 1995, and eight cRCTs
- Chen-Hussey 2013, Hill 2007, Hill 2014, Rowland 1999,
Rowland 2004, Sangoro 2014a, Sluydts 2016, and Syafruddin
2014 - met the inclusion criteria of this Cochrane Review. Data
from McGready 2001 was obtained after we contacted the study
author: the author provided the number of events (malaria cases)
per treatment arm including the number of individuals who had
more than one episode of P. falciparum or P. vivax. Only the first
episode of P. vivax per participant was included in the analysis as
individuals with multiple episodes of vivax malaria might suffer
recurrent episodes of the same infection. We also contacted the
authors of all the cRCTs that did not report ICC (Chen-Hussey
2013; Hill 2007; Sangoro 2014a; Sluydts 2016): only one author
provided the ICC used on their study (Sluydts 2016). The re-
maining studies, for which ICC was not available, were adjusted
for clustering using an estimated ICC of 0.04 - obtained from
Rowland 2004, a cRCT on topical repellents - as per protocol.
Sensitivity analysis was done to evaluate if variation of the esti-
mated ICC resulted in significant change to the main results and
conclusions.
Six studies investigated the impact of topical repellent com-
pared to placebo or no treatment (Chen-Hussey 2013; Hill 2007;
McGready 2001; Rowland 2004; Sangoro 2014a; Sluydts 2016).
In total, 34,281 participants were included in the treatment arms
and 33,016 in the control arms. The studies were conducted in
a variety of countries: Laos (Chen-Hussey 2013), Bolivia (Hill
2007), Thailand (McGready 2001), Pakistan (Rowland 2004),
Tanzania (Sangoro 2014a), and Cambodia (Sluydts 2016). A va-
riety of repellents and concentrations were used: 15% DEET
(Chen-Hussey 2013; Sangoro 2014a); 20% DEET (McGready
2001); 30% PMD (Hill 2007); 20%DEET and 0.5% permethrin
(Rowland 2004); and picaridin (20%picaridin for adults and 10%
picaridin for children) (Sluydts 2016). Three studies usedLLINs as
co-interventions (Chen-Hussey 2013;Hill 2007; Sangoro 2014a).
Most studies included both children and adults in the population;
however one study only included pregnant women (McGready
2001).
Two studies investigated the impact of ITC compared to placebo
or no treatment (Rowland 2004; Soto 1995). In total, 524 indi-
viduals were in the treatment arms, and 473 individuals were in
the control arms. One study was conducted with Afghan refugees
in Pakistan (Rowland 1999); and the other with soldiers based in
Colombia (Soto 1995). We extracted data from Rowland 1999
using inverse variance from adjusted odds ratio and confidence
intervals reported in the article. The study follow-up ranged from
three to 16weeks.Data fromSoto 1995 on recorded adverse events
included data from soldiers who were enrolled in the study and
deployed in leishmania-endemic regions (143 per arm). These in-
dividuals were not part of the component of the study investi-
gating the effect of ITC on malaria incidence but because they
also received the same treatments the results were included in the
review regarding the outcome “recorded adverse events”. No co-
interventions were used in either study.
Two studies investigated the impact of spatial repellents compared
to placebo or no treatment (Hill 2014; Syafruddin 2014). One
study was conducted in China with 1026 households in both the
intervention and control arms.We extracted data fromSyafruddin
2014 and Hill 2014 by using inverse variance from adjusted odds
ratio and confidence intervals reported in the articles. The study
conducted in China had a trial duration of six months and inves-
tigated 0.03% transfluthrin coils in combination with or without
LLINs (Hill 2014). The other study, in Indonesia, was conducted
for a period of 6 months and investigated 0.00975% metofluthrin
coils. Both studies screened at start all participants enrolled for
follow-up and cleared pre-existent malaria infections. Syafruddin
2014 was conducted in two villages with a total population of
2120 but only an active cohort of 170 participants was enrolled
for follow-up (87 in the control arm and 83 in the intervention
arm).These individualswere screened and cleared at start but other
villagers were not. The mosquito coils were rolled out to all vil-
lage households according to treatment allocation (metofluthrin-
treated or placebo coils).
Excluded studies
Six studies were excluded: three studies only had two units of
randomization (Abdulsalam 2014; Hamza 2016; Kimani 2006);
one study did not specify in the published article the repellent
compound that was used - we contacted the corresponding author
but did not receive a response (Deressa 2014); and two were not
RCTs or cRCTs (Dadzie 2013; Eamsila 1994).
Risk of bias in included studies
Overall the risk of bias in the included studies was high (see Figure
2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
Only three studies, Chen-Hussey 2013, Hill 2014, and Sluydts
2016, described proper randomization and allocation concealment
methods, and we therefore graded them as having low risk of se-
lection bias. Rowland 1999 also used an adequate randomization
method but did not clearly describe how allocationwas performed.
We considered two studies, Hill 2007 and Sangoro 2014a, to have
high risk of selection bias because they used alternate allocation
methods. All other studies -McGready 2001, Rowland 2004, Soto
1995, and Syafruddin 2014 - did not provide sufficient informa-
tion to make a judgement about risk of bias and we judged them
as having unclear risk of bias.
Blinding
Most trials were at low risk of bias and adequately blinded partici-
pants and personnel. We judged two trials, Hill 2014 and Sluydts
2016, to have high risk of performance bias as they were not
placebo-controlled. Sluydts 2016 did not provide sufficient infor-
mation on how the clinical data regarding malaria cases were col-
lected and was thus graded as having an unclear risk of bias.
Incomplete outcome data
All studies but one were graded as having low risk of attrition
bias with comparable rates of loss to follow-up between treatment
arms. Rowland 1999 did not report on how many participants
were lost to follow-up from both intervention and control arm
and was thus graded as having unclear risk of bias.
Selective reporting
Selective reporting bias was low for most studies. Three studies,
Rowland 1999, Rowland 2004 and Soto 1995, did not have an
available protocol and were therefore graded as having unclear risk
of bias.
Other potential sources of bias
Two studies, Hill 2007 and Sangoro 2014a, described baseline
imbalances which is considered as a potential source of bias. These
two studies were assessed as having high risk of bias. One study,
Soto 1995, described that soldiers were deployed to endemic areas
for 3-8 weeks but did not report deployment time per arm and so
it was judged as having an unclear risk of baseline bias.
Effects of interventions
See: Summary of findings for the main comparison Topical
repellents compared to placebo or no treatment for malaria
prevention; Summary of findings 2 ITC compared to placebo
or no treatment for malaria prevention; Summary of findings 3
Spatial repellents compared to placebo or no treatment for malaria
prevention
The findings are presented by intervention type (topical repellents,
ITC, and spatial repellents).
Comparison 1: topical repellents compared to
placebo or no treatment for malaria prevention (see
’Summary of findings’ table 1)
Clinical malaria caused by P. falciparum
Three studies investigated the impact on clinical malaria caused
by P. falciparum (Rowland 2004; Sangoro 2014a; Sluydts 2016).
Overall, topical repellents had no impact on clinical malaria (risk
ratio (RR) 0.65, 95% confidence interval (CI) 0.40 to 1.07, 3
studies, 4447 participants, very low certainty evidence; Analysis 1.1)
Figure 3. When sub-grouped by inclusion of LLINs we found one
study that, in the absence of LLINs, reported a significant reduc-
tion in clinical malaria (RR 0.40, 95% CI 0.23 to 0.71, 1 study,
869 participants). There was no significant impact on prevention
of clinical malaria when LLINs were in place (RR 0.84, 95% CI
0.55 to 1.27, 2 studies, 3578 participants). Sensitivity analysis was
done by excluding Sluydts 2016 which was not placebo controlled
and Sangoro 2014a which had high risk of bias because of using an
alternate allocation method. We also performed sensitivity anal-
ysis in regard to the estimated ICC of 0.04 (Sangoro 2014a), by
varying this value between 0.03 and 0.05. The main results did
not change and point estimates remained within the same values.
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Figure 3. Forest plot of comparison: 1 Topical repellent compared to placebo or no treatment, outcome:
1.1 Clinical malaria caused by P. falciparum.
P. falciparum parasitaemia
Four studies investigated the impact on P. falciparum parasitaemia
(Chen-Hussey 2013; Hill 2007; McGready 2001; Sluydts 2016).
Overall, topical repellents had no impact onP. falciparum para-
sitaemia (RR = 0.84, 95% CI 0.64 to 1.12, 4 studies, 13,310
participants, low-certainty evidence; Analysis 1.2) Figure 4. There
continued to be no impact on P. falciparum parasitaemia when
used in conjunction with LLINs (RR 0.91, 95% CI 0.60 to 1.38,
3 studies, 12,413 participants) or without LLINs (RR 0.78, 95%
CI 0.53 to 1.16, 1 study, 897 participants). We conducted a sen-
sitivity analysis by excluding Sluydts 2016 as it was not placebo-
controlled: the point estimate remained the same. Point estimates
were also narrowly affected by removing Hill 2007 from the anal-
ysis due to risk of bias for using alternate allocation. We also per-
formed a sensitivity analysis by varying the ICC that was estimated
for Chen-Hussey 2013 and Hill 2007 of 0.04 between 0.03 and
0.05 and point estimates remained within the same values.
Figure 4. Forest plot of comparison: 1 Topical repellent compared to placebo or no treatment, outcome:
1.2 P. falciparum parasitaemia.
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Clinical malaria caused by P. vivax
Two studies investigated the impact on clinical malaria for P. vi-
vax (Rowland 2004; Sluydts 2016). Overall topical repellents had
no impact on clinical malaria caused by P. vivax (RR 1.32, 95%
CI 0.99 to 1.76, 2 studies, 3996 participants, low-certainty evi-
dence; Analysis 1.3) Figure 5. We conducted a sensitivity analysis
by excluding Sluydts 2016, which was not placebo controlled. The
point estimate remained close to 1 but shifted from favouring the
control to favouring the intervention.
Figure 5. Forest plot of comparison: 1 Topical repellent compared to placebo or no treatment, outcome:
1.3 Clinical malaria caused by P. vivax.
P. vivax parasitaemia
Three studies investigated the impact on P. vivax parasitaemia
(Chen-Hussey 2013; McGready 2001; Sluydts 2016). Overall,
topical repellents had no impact onP. vivax parasitaemia (RR1.08,
95% CI 0.81 to 1.43, 3 studies, 9589 participants, low-certainty
evidence; Analysis 1.4) Figure 6. There continued to be no impact
onP. vivax parasitaemia when used in conjunction with LLINs
(RR 1.24, 95% CI 0.78 to 1.97, 2 studies, 8692 participants)
or without LLINs (RR 0.98, 95% CI 0.68 to 1.40, 1 study, 897
participants). We conducted a sensitivity analysis by excluding
Sluydts 2016, which was not placebo controlled. The main results
did not change although point estimates shifted slightly in favour
of the control. We also performed a sensitivity analysis by varying
the ICC, estimated for Chen-Hussey 2013 at 0.04, between 0.03
and 0.05: point estimates remained within the same values.
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Figure 6. Forest plot of comparison: 1 Topical repellent compared to placebo or no treatment, outcome:
1.4 P. vivax parasitaemia.
Anaemia
One study investigated the impact on anaemia (McGready 2001).
Topical repellents had no impact on anaemia (RR 1.06, 95% CI
0.91 to 1.23, 1 study, 587 participants; Analysis 1.5).
All-cause fever
One study investigated the impact on all-cause fever (Hill 2007).
Participants that used topical repellents were half as likely to de-
velop a fever when compared to participant in the control arm (RR
0.44, 95% CI 0.35 to 0.55, 1 study, 3496 participants; Analysis
1.6).
Adherence to the intervention
Five studies reported adherence to the intervention (Chen-Hussey
2013;Hill 2007;McGready 2001; Sangoro 2014a; Sluydts 2016).
All five report self-reported adherence, measured monthly or
weekly or non-periodically. Four studies report a variety of meth-
ods of objective monitoring of adherence: estimating weight of
repellent bottles (Chen-Hussey 2013; Hill 2007); random sniff
checks or spot checks (Hill 2007; McGready 2001); number of
bottles issued to households (Sangoro 2014a). Two studies re-
ported the proportion of participants that have been adherent to
the intervention. Chen-Hussey 2013 reported 61.3% adherence
in the intervention arm and 62.2% in the control arm. Hill 2007
reported 98.5% compliance in both arms (Analysis 1.7).
Adverse events
Four studies reported adverse events (Hill 2007; McGready 2001;
Rowland 2004; Sluydts 2016). Three studies used interviews to as-
sess the occurrence of adverse events (Hill 2007; McGready 2001;
Rowland 2004), of which one study also provided a questionnaire
to a small sample of the study population (Rowland 2004). Sluydts
2016 did not describe themethods ofmeasuring and recording ad-
verse events. Very few adverse events were reported, and all related
to skin irritation or warming sensation (Analysis 1.8). McGready
2001 reported the occurrence of adverse events to 6% of the par-
ticipants but did not specify the nature of the adverse events or
in which treatment arm they had occurred. We contacted the au-
thors, and they informed us that all adverse events had been de-
scribed as skin warming sensation and had been restricted to the
study arm that had been allocated thanaka with 20% DEET. No
serious adverse events were reported requiring intervention dis-
continuation.
Other outcomes
No data were available for the comparisons of reduction in
mosquito bites and time to first infection.
Comparison 2: ITC compared to placebo or no
treatment for malaria prevention (see ’Summary of
findings’ table 2)
Clinical malaria caused by P. falciparum
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Two studies investigated the impact on clinical malaria caused
byP. falciparum (Rowland 1999; Soto 1995). Overall, ITC halved
the incidence of clinical malaria (RR 0.49, 95% CI 0.29 to 0.83,
2 studies, 997 participants, low-certainty evidence; Analysis 2.1;
Figure 7). Results remained the same after we conducted a sensi-
tivity analysis by excluding Rowland 1999 (cRCT).
Figure 7. Forest plot of comparison: 2 ITC compared to placebo or no treatment, outcome: 2.1 Clinical
malaria caused by P. falciparum.
Clinical malaria caused byP. vivax
Two studies investigated the impact on clinical malaria for P. vi-
vax (Rowland 1999; Soto 1995). Overall, ITC reduced by 64%
the risk of clinical malaria caused by P. vivax (RR 0.64, 95% CI
0.40 to 1.01, 2 studies, 997 participants, low-certainty evidence;
Analysis 2.2) Figure 8. After we carried out a sensitivity analysis
by excluding Rowland 1999 (cRCT) results shifted in favour of
the intervention but had wider confidence intervals, crossing the
point estimate of no effect.
Figure 8. Forest plot of comparison: 2 ITC compared to placebo or no treatment, outcome: 2.2 Clinical
malaria caused by P. vivax.
Adverse events
Two studies reported adverse events from interviews with partici-
pants (Rowland 1999; Soto 1995). Only two events of skin irrita-
tion were reported in the 997 participants across the two studies
(Analysis 2.3). No serious adverse events requiring trial discontin-
uation were reported.
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Other outcomes
No data were available for the comparison of the following out-
comes: P. falciparum parasitaemia, P. vivax parasitaemia, time to
first infection, anaemia, all-cause fever, adherence to the interven-
tion, and reduction in mosquito bites.
Comparison 3: spatial repellents compared to
placebo or no treatment for malaria prevention (see
’Summary of findings’ table 3)
Plasmodium species’ parasitaemia
Hill 2014 investigated the impact of spatial repellents on bothP.
falciparum and P. vivax infections. Syafruddin 2014 did not differ-
entiate betweenPlasmodium species and presented incidence num-
bers of malaria irrespective of causing agent. Both studies cleared
P. vivax infections at start. In order to allow a meta-analysis and
compare data from both studies, we combined the data from Hill
2014 into total number of infections caused byPlasmodium species
(13 cases in total: repellent arm reported 1 case of P. falciparum
and the control arm reported 2 cases of P. falciparum and 10 of
P. vivax). The papers reported results adjusted for clustering and
we extracted these data and entered them in the analysis. Results
from the meta-analysis show that spatial repellents had no im-
pact onPlasmodium species’ parasitaemia (RR 0.24, 95% CI 0.03
to 1.72, 2 studies, 6683 participants, very low certainty evidence;
Analysis 3.1) Figure 9.
Figure 9. Forest plot of comparison: 3 Spatial repellents compared to placebo or no treatment, outcome:
3.1 Plasmodium spp. parasitaemia.
Adherence to the intervention
One study - Hill 2014 - reported adherence to the intervention
through self-reporting and counting of empty coil boxes using a
monthly survey. Hill 2014 reported compliance between 89.3%
and 97.8% in the control arm and between 98.5% and 98.6% in
the treatment arm (Analysis 3.2).
Reduction in mosquito bites
One study reported reduction in mosquito bites (Hill 2014). The
mean number of bites was 2.1 in the spatial repellent arm (standard
deviation (SD) 1.9) and 12.9 (SD7.6) in the control arm (Analysis
3.3). Syafruddin 2014 also measured the reduction in mosquito
bites caused by use ofmetofluthrin coils. Syafruddin 2014 reported
a 32.9% reduction in mosquito landings in households using the
metofluthrin coils, however the data presented in the article could
not be extracted and added to the meta-analysis.
Adverse events
One study investigated adverse events related to the use of
mosquito coils (Syafruddin 2014). Participants were interviewed
during random spot-checks and asked if any adverse event had
occurred. No adverse events were reported.
Other outcomes
No data were available for the comparison of the following out-
comes: clinical malaria caused by P. falciparum or P. vivax; time to
first infection; anaemia; and all-cause fever.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
ITC compared to placebo or no treatment for malaria prevention
Patient or population: malaria prevent ion
Setting: malaria-endemic regions
Intervention: ITC
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo or no
treatment
Risk with ITC
Clinical malaria: P. falci-
parum
35 per 1000 17 per 1000
(10 to 29)
RR 0.49
(0.29 to 0.83)
997
(2 studies)
⊕⊕©©
LOW1,2
Due to risk of bias and
imprecision
Insec-
t icide-treat ing clothing
may have a protect ive
ef fect against malaria
caused by P. falciparum.
Our conf idence in the
ef fect est imate is lim-
ited. The true ef fect
may be substant ially
dif f erent f rom the est i-
mate of the ef fect
Clinical malaria: P. vivax 116 per 1000 74 per 1000
(47 to 117)
RR 0.64
(0.40 to 1.01)
997
(2 studies)
⊕⊕©©
LOW1,2
Due to risk of bias and
imprecision
In-
sect icide-treated cloth-
ing may have a pro-
tect ive ef fect against
malaria caused by P.
vivax. Our conf idence
in the ef fect est imate
is lim ited. The true ef -
fect may be substan-
t ially dif f erent f rom the
est imate of the ef fect2
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*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for risk of bias: Soto 1995 did not describe how randomizat ion and allocat ion concealment was assured;
and had unclear risk of baseline bias because did not report how long soldiers in each arm were deployed to malaria
endemic areas. Rowland 1999 did not describe the method used for allocat ion concealment.
2Downgraded by 1 for imprecision: the sample sizes and number of events are very small.
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Spatial repellents compared to placebo or no treatment for malaria prevention
Patient or population: malaria prevent ion
Setting: malaria-endemic regions
Intervention: spat ial repellents
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo or no
treatment
Risk with Spatial repel-
lents
Parasitaemia Plasmod-
ium spp.
10 per 1000 2 per 1000
(0 to 18)
RR 0.24
(0.03 to 1.72)
6683
(2 studies)
⊕©©©
VERY LOW1,2,3
Due to risk of bias, im-
precision and inconsis-
tency
We do not know if
spat ial repellents pro-
tect against malaria.
We have very lit t le con-
f idence in the ef fect es-
t imate. The true ef fect
is likely to be substan-
t ially dif f erent f rom the
est imate of ef fect
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for risk of bias: Hill 2014 was not blinded.
2Downgraded by 1 for imprecision: Hill 2014 was underpowered and reported very few events (1/ 3349 in the intervent ion and
11/ 3270 in the control), and the CIs ranged f rom no ef fect to large benef its. Both studies were underpowered.
3Downgraded by 1 for inconsistency: there is considerable unexplained heterogeneity between trials (I² stat ist ic = 46%)
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D I S C U S S I O N
We have discussed the findings of the main outcomes by interven-
tion type (topical repellents, ITC, and spatial repellents).
Summary of main results
Topical repellents
Results from the overall meta-analysis indicate that the included
trials did not demonstrate that topical repellents have a protec-
tive effect against clinical malaria caused by either P. falciparum
or P. vivax (very low certainty evidence and low-certainty evidence
respectively). The same was observed in trials that used active case
detection and measured the effect of topical repellents on malaria
parasitaemia caused by P. falciparum or P. vivax (low-certainty evi-
dence). Regarding P. vivax infections, topical repellents may in fact
increase the risk of infection. However, it is unclear if this result
has a plausible biological explanation or if the finding was due to
confounding factors. The most likely possible confounding factor
is the recrudescent infections that may have been unbalanced be-
tween study arms because none of the studies investigating topical
repellents cleared parasites at start. Subgroup analysis was under-
taken to assess trials conducted with and without LLINs as co-
interventions. Only two studies, which were both conducted with
displaced populations, did not include LLINs. Rowland 2004 re-
ported fewer P. falciparummalaria cases in the intervention group
given repellent soap (RR 0.40, 95% CI 0.23 to 0.71); however
McGready 2001 measured no reduction in malaria infection in-
cidence by either P. falciparum or P. vivax. Trials where LLINs
were distributed to the participants and repellents were used as an
additional protective generally reported no additional protection
against malaria.
Compliance was an issue in the included studies (see Table 1).
Most studies reported poor compliance or difficulty in reliably
measuring compliance. Most studies used self-reporting methods
such as interviews and questionnaires or indirect methods such as
weighing bottles or counting bottles of repellents. These methods
are not reliable as participants may lie to please the investigating
team (response bias), dispose of the repellent or share the repel-
lent bottles with others. Sluydts 2016 conducted an observational
study where compliance was evaluated in a pool of households
from different clusters and observed compliance between 6% and
15%, as opposed to self-reported compliance of 70%. Other stud-
ies - Chen-Hussey 2013 and Sangoro 2014a - also reported diffi-
culties measuring compliance. Self-reported compliance was gen-
erally found to be high (> 80%); however the unreliable nature
of the data might overestimate compliance. The issue of compli-
ance may relate to product acceptability. Social studies showed
that participants liked using topical repellents (Rowland 2004),
but often forgot to use them or did not use them appropriately
(Chen-Hussey 2013). It is questionable if topical repellents can
be used for malaria prevention in the general population as daily
compliance and poor standardization (amount of repellent used,
surface area applied, time of application, and period between re-
peated applications) are major limitations of this intervention. In
addition, poor compliance leads to a decrease in study power and
requires studies with very large numbers of participants which are
also increasingly unfeasible as malaria prevalence drops across re-
gions.
The included studies were performed in diverse ecological and
epidemiological settings (see Table 2), across hypo-endemic re-
gions (malaria prevalence < 5%) (Chen-Hussey 2013; Hill 2007;
Sluydts 2016), and meso-endemic regions (malaria prevalence 5%
to 15%) (McGready 2001; Rowland 2004; Sangoro 2014a), us-
ing both active and passive case detection and different diagnostic
methods (see Table 3). We used malaria prevalence data from each
study’s control to calculate the necessary sample size and noted
that except for Rowland 2004, which was only slightly under-
powered, all other studies were severely underpowered. Even the
very large trial that was conducted in Cambodia with over 48,000
participants was severely underpowered, effectively needing over
half a million participants to reach its objectives (Sluydts 2016).
Reasons included the very low prevalence of malaria in the study
area (< 2%) as well as the large size of the clusters which reduced
the effective sample size after adjusting for clustering. The sam-
ple size estimation that we calculated assumed 100% compliance,
which is unrealistic, meaning that the sample sizes would need
to be even larger. The sample size for a cRCT aiming to investi-
gate the effect of topical repellents on malaria needs to be so large
that its feasibility is questionable, making it arguable if RCTs and
cRCTs are the best methodology. There is undeniable evidence
from entomological studies that topical repellents can provide bite
protection from mosquitoes and reduce vector human contact,
making them a very efficient personal protection tool, but our
review results conclude that, despite their high efficiency, topical
repellents as an intervention might have very poor effectiveness
with regard to malaria prevention.
ITC
Results from themeta-analysis trials indicate that ITCmay protect
against clinical malaria caused by either P. falciparum or P. vivax
(low-certainty evidence). The studies were conducted with soldiers
and refugees who did not have access to LLINs or other personal
protection tools. Compliance with the intervention was not mea-
sured in either trial but it is highly likely to have been high, given
the limited options of soldiers and refugees with regard to cloth-
ing. Also, studies reported that participants perceived additional
protection from other insects, such as fleas and bedbugs, suggest-
ing a high product acceptability.
Spatial repellents
A meta-analysis of the outcome Plasmodium species’ parasitaemia
was performed. Both studies clearedP.vivax infections at start (Hill
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2014; Syafruddin 2014). Results from the meta-analysis did not
demonstrate a protective effect of spatial repellents against ac-
quiring Plasmodium species’ parasitaemia (very low certainty evi-
dence). There was a considerable heterogeneity between the stud-
ies and very large confidence intervals around the point estimates.
The studies used two different volatile pyrethroids: Hill 2014
used transfluthrin 0.03% and Syafruddin 2014 used metofluthrin
0.00925%. However this difference between the studies is an un-
likely explanation for the observed heterogeneity because both
compounds were tested before trial start and reported to reduce
vector biting rates (Barbara 2011; Hill 2014). Hill 2014 was
severely underpowered and reported very few events - the study
took place in an area with very lowmalaria transmission (see Table
2). Syafruddin 2014was done in an areawith highermalaria preva-
lence (see Table 2); however it only followed up 170 individuals
(83 in the intervention arm and 87 in the control arm) and was
also underpowered.
Overall completeness and applicability of
evidence
Studies on topical repellents were undertaken in various malaria-
endemic countries (Bolivia, Cambodia, Laos, Pakistan, Tanzania,
and Thailand) with malaria prevalence ranging between 0.31%
and 11.4% forP. falciparum and 0.4% and 11.8% for P. vivax (see
Table 2). Most studies were conducted with entire resident com-
munities, involving adults and children of all ages. One study fo-
cused strictly on displaced pregnant women of Karen ethnicity in
Thailand;and one study was conducted amongst Afghan refugees
in a refugee camp in Pakistan. Some of the studies investigated
topical repellents as complementary tool to LLINs. Given that
LLINs are highly effective against malaria and are the backbone of
all national malaria control programs, studies that did not include
them may not be providing useful information to policy makers.
However the included studies that did not use LLINs were con-
ducted with vulnerable displaced populations and therefore the
results may still be applicable to disaster situations or other situ-
ations where LLIN use may be compromised. Compliance may
have affected the results of some of the included studies; how-
ever low compliance reflects what is likely to happen in the ’real
world’ and suggests that topical repellents may not be an option
for malaria control programmes.
With regard to ITC, no study has been done in the general pop-
ulation. Both studies involved vulnerable populations: soldiers
deployed in malaria-endemic regions (Soto 1995); and refugees
(Rowland 1999). These populations are exposed to a higher risk
of malaria, potentially have lower immunity than resident popu-
lations of that endemic area, live in harsher conditions and poten-
tially wash their clothing less frequently and differently compared
to the general population. This might have implications on the
efficacy and effectiveness of the intervention. It is arguable if the
results from our meta-analysis are applicable to the general pop-
ulation; further studies on civilian and undisplaced populations
would be of interest to policy makers as ITC may to some extent
reduce the risk of malaria. It is also important to evaluate the ben-
efit of using ITC in combination with LLINs, as studies available
so far did not include LLINs in their design and may not provide
adequate information on the additional protection it may provide
to populations who already use LLINs.
Two studies investigating spatial repellentsmet the inclusion crite-
ria for this review. The studies were both conducted in Asia (China
and Indonesia) amongst the general population. It is unclear if the
studies could be representative of other regions.
This review focused onmalaria; however,mosquito repellents may
have a broader applicability in regard to protection from other vec-
tor-borne diseases particularly transmitted by Aedes mosquitoes,
such as dengue, chikungunya, and Zika viruses. An additional
systematic review addressing this limitation would summarize the
available evidence of the effect of this intervention on Aedes-borne
diseases.
Quality of the evidence
The results of the main outcomes were graded as either very low
or low-certainty evidence. We downgraded mainly due to risk of
bias generated by improper methodologies for random sequence
generation and allocation concealment; and by imprecision, as
most studies were severely underpowered, estimates had wide con-
fidence intervals, there were very few events, and the point esti-
mate included the point of no effect (RR = 1). In the case of spatial
repellents we also downgraded for inconsistency, as trials reported
very different results, leading to a high degree of unexplainable
heterogeneity.
Potential biases in the review process
We attempted to minimize bias in the review process by conduct-
ing a comprehensive search of published and unpublished litera-
ture, without language restrictions. Two review authors, who had
no involvement in the included study, independently screened ab-
stracts, extracted data and assessed risk of bias. We resolved any
discrepancies by involving a third review author. We were unable
to create funnel plots to assess reporting biases, since fewer than 10
RCTs/cRCT per intervention (topical repellents, ITC and spatial
repellents) met the inclusion criteria.
Agreements and disagreements with other
studies or reviews
A systematic review done by Wilson 2014 which included ran-
domized and non-RCTs on topical repellents concluded that these
are unlikely to provide effective protection against malaria and
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called for further well-designed trials. Our findings are in accor-
dance with Wilson 2014, as we also conclude that there is insuffi-
cient evidence to make recommendations regarding topical repel-
lents for malaria prevention. We did not find any other systematic
review which aimed to investigate the effect of spatial repellents
or ITC on malaria prevention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are unable to make well-informed recommendations with re-
gard to including or not including topical repellents, ITC, or spa-
tial repellents in malaria control programmes as the available evi-
dence is low to very low certainty. The use of ITC in refugee camps
or disaster situations may be useful as ITC provided some malaria
prevention; however further research needs to be done in order to
generate stronger evidence to support this.
Implications for research
We conclude that there are insufficient well-designed trials on top-
ical repellents to draw evidence-based conclusions and make well-
informed recommendations to policy makers regarding tropical
repellents as a malaria prevention tool. However, there is lean ev-
idence that the use of ITC may be useful in refugee camps or
other disaster settings as they provided some malaria prevention in
the absence of LLINs; further research needs to be done in order
to generate stronger evidence to support this. There is a need to
consider methodologies other than RCTs and cRCTs for the eval-
uation of malaria prevention methods such as topical repellents,
ITC and spatial repellents at community level. Low compliance
alongside decreasing malaria prevalence levels in potential study
sites are major limitations for the design of future RCT or cRCTs
because an unfeasible number of participants would need to be
followed up to reach sufficient statistical power. All of the trials
considered in this review were considered to be underpowered,
including Sluydts 2016 which recruited over 20,000 participants
per arm. Further studies on ITC involving general populations are
needed to broaden the applicability of the results and to increase
the certainty of the evidence. We also conclude that there are in-
sufficient studies on spatial repellents to generate evidence-based
conclusions regarding spatial repellents for malaria prevention.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chen-Hussey 2013
Methods Cluster randomized controlled trial (RCT)
Unit of randomization was household.
Intra-cluster correlation coefficient (ICC) was not reported
Trial duration: up to 8 months’ follow-up in 2009 and 2010
Participants Adults or children living in endemic regions of Laos in Attapeu Sekong Provinces
Participants were not screened at start for P. vivax.
Interventions Topical repellent: 15% DEET and placebo
Co-interventions: LLINs
Treatment arms:
- Repellent arm: 795 households; 3972 participants; and
- Placebo arm: 802 households; 4008 participants.
Outcomes - Participants with malaria parasitaemia confirmed through mRDTs (P. falciparum or P.
vivax);
- Time to first infection (mean time in person/months to first malaria infection); and
- Self-reported adherence to regular usage of the intervention
Notes Conducted in Laos.
Trial registration number: NCT00938379
Funded by Population Services International.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Equal group allocation, stratified by vil-
lage.Heads of households picked treatment
codes through lottery system
Allocation concealment (selection bias) Low risk Heads of households picked treatment
codes out of a bowl.
Blinding of participants and personnel
(performance bias)
Parasitaemia
Low risk The treatment allocation was blinded to
both participants and field staff
Blinding of participants and personnel
(performance bias)
Time to first infection
Low risk The treatment allocation was blinded to
both participants and field staff
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Chen-Hussey 2013 (Continued)
Blinding of participants and personnel
(performance bias)
Compliance
Low risk The treatment allocation was blinded to
both participants and field staff
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Assessment of parasitaemia or time to first
infection are objective outcomes
“Field staff carrying out randomisation and
follow-up surveys and trial staff performing
data entry and analysis were blinded for the
length of the trial.”
Blinding of outcome assessment (detection
bias)
Time to first infection
Low risk Assessment of parasitaemia or time to first
infection are not biased because these are
objective outcomes
Blinding of outcome assessment (detection
bias)
Compliance
Low risk The treatment allocation was blinded to
both participants and field staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition between 2 groups: 11.
7% in intervention and 13.2% in control
groups were lost to follow-up/excluded/
withdrew
Selective reporting (reporting bias) Low risk Primary outcome was reported as per pro-
tocol. Secondary outcomes included all-
cause fever, but this was not reported; how-
ever it is non-essential information for this
study
The data presented on compliance was self-
reported, there was no reporting of compli-
ance measured through “sniff-checks” al-
though it was described in theMethods sec-
tion
Other bias Low risk Baseline imbalance
Study arms had similar baseline character-
istics.
Hill 2007
Methods Cluster-RCT
Unit of randomization: household
ICC was not reported.
Trial duration: 6 months from March to September 2003.
Participants Adults or children living in malaria-endemic area
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Hill 2007 (Continued)
Interventions Topical repellent lotion containing 30% PMD versus placebo lotion
Co-interventions: LLINs
Treatment arms:
- Repellent arm (30% PMD) + LLINs: 424 households (1967 individuals)
- Placebo arm + LLINs: 436 households (2041 individuals)
Outcomes - Participants with malaria parasitaemia confirmed through mRDTs (specific to P. falci-
parum);
- All-cause fever;
- Self-reported adherence to regular usage of the intervention; and
- Recorded adverse events.
Notes Conducted in the Bolivian Amazon, Vaca Diez and Pando Provinces
Trial registration number: NCT00144716
FundedbyGatesMalaria Partnership grant fromLondon School ofHygiene andTropical
Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence generation was not random.
“Field staff followed the strict inclusion
criteria to randomise participants at the
household level following a basic sequential
alternate A/B/A/B regimen. Field staff and
study participants were blind to the group
allocation.”
Allocation concealment (selection bias) High risk Sequence generation was alternated. Per-
sonnel knew which treatment was given
next
“Field staff followed the strict inclusion
criteria to randomise participants at the
household level following a basic sequential
alternate A/B/A/B regimen. Field staff and
study participants were blind to the group
allocation.”
Blinding of participants and personnel
(performance bias)
Parasitaemia
Low risk Field staff and participants were blinded to
the treatment allocation
Blinding of participants and personnel
(performance bias)
All-cause fever
Low risk Field staff and participants were blinded to
the treatment allocation
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Hill 2007 (Continued)
Blinding of participants and personnel
(performance bias)
Compliance
Low risk Field staff and participants were blinded to
the treatment allocation
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Field staff and participants were blinded to
the treatment allocation
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Primary outcome is objective (mRDT re-
sult), so although it is not described if the
outcome assessor is blinded, lack of blind-
ing was unlikely to bias the results
Blinding of outcome assessment (detection
bias)
Compliance
Unclear risk Blinding of outcome assessment for adher-
ence to intervention is unclear
Blinding of outcome assessment (detection
bias)
All-cause fever
Unclear risk Blinding of outcome assessment for all-
cause fever is unclear
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Blinding of outcome assessment for adverse
events is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of participants lost to follow-
up was similar between treatment arms
Selective reporting (reporting bias) Low risk All the outcomes set to be measured were
reported.
Other bias High risk Baseline imbalance
“There were no significant differences in
most household characteristics (number of
household members, roof material, water
source, heating source, or possession of
electricity, fridge, and radio) between the
two groups (data not shown), but house-
holds allocated to the repellent group were
slightlymore likely to own a television than
those allocated to the placebo group (P=0.
056) (table 1). There were also no signifi-
cant differences in age or sex between the
groups but at baseline more participants in
the repellent group were positive for P. fal-
ciparum (P=0.065) (table 1).”
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Hill 2014
Methods Cluster-RCT
Unit of randomization: household
ICC is not reported.
Trial duration: 1month baseline and 6months’ intervention fromApril to October 2007
Participants Adults or children living in an endemic region
Participants were screened forP. vivax and parasites were cleared at start.
Interventions Mosquito coils (0.03% transfluthrin) and no treatment.
Co-interventions: LLINs
Treatment arms:
- Control (no treatments) arm 513 households
- 0.03% transfluthrin coils arm 512 households
- LLINs arm 513 households
- LLINs + 0.03% transfluthrin coils arm 514 households
Outcomes - Participants with malaria parasitaemia confirmed through mRDTs (P. falciparum or P.
vivax) and verified by external microscopist through thick film;
- Adherence to regular usage of the intervention measured through village leaders’ reports
and self-reporting; and
- Reduction in indoor density of mosquitoes measured through collections using CDC
light traps indoor households from the four treatment arms (monthly arithmetic mean
of mosquito densities)
Notes Conducted in rural areas of China in the Ruili County, Yunnan Province, close to the
Myanmar border
Trial registration number: NCT00442442
Funded by SC Johnson
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done using lottery system:
“Households enrolled at baseline were ran-
domly allocated by the lottery method to
one of the four intervention arms (i) noth-
ing, (ii) coils alone, (iii) LLINs alone or (iv)
coils and LLINs.”
Allocation concealment (selection bias) Low risk Allocation was done using lottery system so
allocation was concealed:
“Households enrolled at baseline were ran-
domly allocated by the lottery method to
one of the four intervention arms (i) noth-
ing, (ii) coils alone, (iii) LLINs alone or (iv)
coils and LLINs.”
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Hill 2014 (Continued)
Blinding of participants and personnel
(performance bias)
Parasitaemia
High risk Participants and field staff were not
blinded. Participants may have changed
their behaviour if they knew towhich treat-
ment they had been allocated
“Field workers and participants were not
blinded to treatment allocation, as this was
impossible in practice. However, the field
staff collectingmonthlyRDTdatawere not
aware of the interventionwhich individuals
had been using thus achieving single blind-
ing (investigator) of the study.”
Blinding of participants and personnel
(performance bias)
Compliance
High risk Participants and field staff were not
blinded. Participants may have changed
their behaviour by knowing the treatment
they had been allocated to
“Field workers and participants were not
blinded to treatment allocation, as this was
impossible in practice. However, the field
staff collectingmonthlyRDTdatawere not
aware of the interventionwhich individuals
had been using thus achieving single blind-
ing (investigator) of the study.”
”…the untreated control group continued
to use their own personal protection meth-
ods. It would be unethical to ask anyone
not to do this but a record was kept of
such ad-hoc coil use in the negative control
group and those reporting the use of one
box or more (10 coils/5 nights) were ex-
cluded from the analysis for that round.(...
) Conversely, those in the control arm were
less likely to follow the request of the study
directors to not use any intervention, with
13-19% using local coils for 3 or more days
in the month prior to the survey.”
Blinding of participants and personnel
(performance bias)
Reduction in mosquitoes attempting to
feed on humans
High risk The team collecting the mosquitoes could
have been biased if they knewwhich houses
belonged to each treatment
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Staff assessing parasitaemia were blinded.
”However, the field staff collectingmonthly
RDT data were not aware of the inter-
vention which individuals had been us-
ing thus achieving single blinding (inves-
tigator) of the study.Furthermore, micro-
scopist’s at Yunnan Institute of Parasitic dis-
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Hill 2014 (Continued)
eases that verified positive RDTs by mi-
croscopy and the statistician was blind to
the allocation.”
Blinding of outcome assessment (detection
bias)
Compliance
High risk Compliance was measured indirectly
through counting of empty boxes of coils
Blinding of outcome assessment (detection
bias)
Reduction in mosquitoes attempting to
feed on humans
Low risk Data is objective therefore the risk of de-
tection bias is low
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was less than 2% in all
treatment arms.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias Low risk Baseline imbalance
Study arms had similar baseline character-
istics.
McGready 2001
Methods RCT
Trial duration: 17 months between April 1995 and September 1996
Participants Participants were women who were 3 to 7 months’ pregnant.
Participants were not screened at start for P. vivax.
Interventions 20% DEET added to Thanaka (popular local cosmetic) compared to Thanaka alone
Co-intervention: none
Treatment arms:
- Thanaka containing 20% DEET arm 449; and
- Thanaka arm 448.
Outcomes - Participants with malaria parasitaemia confirmed through blood smears (P. falciparum
andP. vivax);
- Adherence to regular usage of the intervention measured through self-reporting;
- Anaemia; and
- Recorded adverse events.
Notes The study was carried out in camps for displaced people of the Karen ethnic minority
in endemic regions of Thailand
The project was funded by the Danish Bilharziasis Laboratory and was part of the Well-
come Mahidol University of Oxford Tropical Medicine Research Programme funded
by the Wellcome Trust
Risk of bias
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McGready 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Parasitaemia
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of participants and personnel
(performance bias)
Anaemia
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of participants and personnel
(performance bias)
Compliance
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of outcome assessment (detection
bias)
Compliance
Low risk Double blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Double-blinded RCT, both personnel and
participants were blinded to the interven-
tion
Blinding of outcome assessment (detection
bias)
Anaemia
Low risk This is an objective outcome.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition between arms was similar, data
was not reported in the published but re-
trieved through communication with the
author
Selective reporting (reporting bias) Low risk Reporting was not clear in the published
article but data of events between treatment
arms was sent to us after communicating
with the author
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McGready 2001 (Continued)
Other bias Low risk Baseline imbalance
“Between April 1995 and September 1996,
897 pregnant women were enrolled in the
study, 449 into the DET and thanaka
group and 448 into the thanaka alone
group with no difference in baseline char-
acteristics”
Rowland 1999
Methods Cluster-RCT
Unit of randomization: household
ICC was not reported.
Trial duration: 16 weeks from July to November 1996
Participants Adults or children living in malaria-endemic regions
Participants were not screened at start for P. vivax.
Interventions Treated clothing in the form of chaddars (permethrin 0.1 mg/cm²) versus placebo
Co-interventions: none
Treatment arms:
- Treated chaddar arm: 51 households (438 individuals)
- Placebo arm: 51 households (387 individuals)
Outcomes - Participants with clinical malaria confirmed through blood smears or rapid diagnostic
tests (P. falciparum or P. vivax); and
- Recorded adverse events.
Notes Trial was conducted with Afghan refugees in Adizai settlement in north-western Pakistan
Funded by HealthNet International’s Malaria and Leishmaniasis control and research
programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomnumber generator used against list
of health centre family registration cards
“To achieve this sample size, 20%of refugee
households were selected using a random
number generator against the
list of health centre family registration
cards.”
Allocation concealment (selection bias) Unclear risk Not described.
“Selected households were randomly di-
vided into intervention and placebo
groups, and if more than one family lived
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Rowland 1999 (Continued)
in a single house all families therein were
allocated to the same treatment group.”
Blinding of participants and personnel
(performance bias)
Clinical malaria
Low risk Participants and staff were blinded.
“Field workers were under the assumption
that both placebo and permethrin were ef-
fective. Health centre staff did not know
which families were in
which group.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Participants and staff were blinded.
“Field workers were under the assumption
that both placebo and permethrin were ef-
fective. Health centre staff did not know
which families were in which group.”
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk “Health centre staff did not know which
families were in which group“
Blinding of outcome assessment (detection
bias)
Clinical malaria
Low risk “Health centre staff did not know which
families were in which group”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated how many people were lost to
follow-up, or how/if this was measured
Selective reporting (reporting bias) Unclear risk Protocol not available and author failed to
communicate with the review team
Other bias Low risk Baseline imbalance
Study arms had similar baseline character-
istics.
Rowland 2004
Methods Cluster-RCT
Unit of randomizations: household
Intra-cluster correlation coefficient factor of 0.04.
Trial duration: 7 months between August 1999 and February 2000
Participants Adults and children living in malaria-endemic regions
Participants were not screened at start for P. vivax.
Interventions Topical repellent - Mosbar soap (20% DEET + 0.5% permethrin) versus placebo lotion
Co-interventions: none
Treatment arms:
- Mosbar soap (20% DEET + 0.5% permethrin) arm: 67 households (618 participants)
- Placebo arm: 60 households (530 participants)
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Rowland 2004 (Continued)
Outcomes - Participants with clinical malaria confirmed through blood smears or rapid diagnostic
tests (P. falciparum or P. vivax); and
- Recorded adverse events.
Notes Trial was conducted with Afghan refugees in malaria-endemic region of Pakistan
Funded by HealthNet International’s Malaria and Leishmaniasis control and research
programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
“By applying simple randomisation 13%
(67 of 510) of households were allocated
to the repellent soap group and a similar
proportion (12%, 60 of 510) to the placebo
control.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
Clinical malaria
Low risk Participants were blinded: although they
had been given two different products, a
soap or a lotion, they were not aware which
one had repellent properties
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Participants and personnel were blinded.
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Participants and personnel were blinded.
Blinding of outcome assessment (detection
bias)
Clinical malaria
Low risk Microscopists were blinded to the treat-
ment allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up were reported.
Selective reporting (reporting bias) Unclear risk Protocol not available and author failed to
communicate with the review team
Other bias Low risk Baseline imbalance
Study arms had similar baseline character-
istics.
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Sangoro 2014a
Methods Cluster-RCT
Unit of randomization: cluster of houses
ICC is not reported.
Trial duration: 14 months from July 2009 to August 2010
Participants Adults or children living in endemic areas.
Interventions 15% DEET lotion versus placebo lotion
Co-interventions: LLINs
Treatment arms:
- DEET 15% + LLINs arm 10 clusters, 468 households and 2224 participants
- Placebo + LLINs arm 10 clusters, 469 households and 2202 participants
Outcomes - Participants with clinical malaria confirmed through blood smears or rapid diagnostic
tests (P. falciparum); and
- Adherence to regular usage of the intervention.
Notes Trial was conducted in rural communities of the Ulanga district, Kilombero Valley,
Tanzania
Trial registration number: ISRCTN92202008
Funded by Population Services International.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence generationwas done using lottery
system.
Allocation concealment (selection bias) High risk Allocation was not concealed. The method
described was basic sequential alternate A/
B/A/B
Blinding of participants and personnel
(performance bias)
Clinical malaria
Low risk The treatment allocation was blinded to
both participants and field staff
Blinding of participants and personnel
(performance bias)
Compliance
Low risk The treatment allocation was blinded to
both participants and field staff
Blinding of outcome assessment (detection
bias)
Compliance
High risk Compliance was indirectly reported by
measuring the amount of lotion remaining
in the bottle
Blinding of outcome assessment (detection
bias)
Clinical malaria
Low risk Clinical malaria was diagnosed by mRDT
which is an objective method
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Sangoro 2014a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up and withdrawals were
identical between treatment groups
Selective reporting (reporting bias) Low risk All outcomes were reported.
Other bias High risk Baseline imbalance:
“Bias was introduced into the study by
an imbalance in socio-economic status be-
tween the two study groups. The control
group demonstrated a higher socio-eco-
nomic status than the control arm.”
Sluydts 2016
Methods Cluster-RCT
Unit of randomization: cluster of houses
ICC was calculated per survey; survey 4 ICC was 0.0294.
Trial duration: approximately 20months fromApril 2012untilNovember 2013 inclusive
Participants Adults and children living in malaria-endemic regions.
Participants were not screened at start for P. vivax.
Interventions Picaridin KBR3023 (topical repellent) versus no treatment
Picaridin 10% for children < 10 years and Picaridin 20% in individuals < 10 years
Co-interventions: LLINs
Treatment arms:
- Picaridin KBR3023 arm 49 clusters from 57 villages (5642 households, 25,051
individuals)
- No treatment arm 49 clusters from 56 villages (5287 households, 23,787 individuals)
Outcomes - Participants with clinical malaria confirmed through blood smears or rapid diagnostic
tests (P. falciparum or P. vivax);
- Participants with malaria parasitaemia confirmed through thick or thin blood smears,
mRDTs or PCR (P. falciparum or P.vivax);
- Adherence to regular usage of the intervention through self-reporting and observational
studies; and
- Recorded adverse events.
Notes Trial was conducted in Ratanakiri province, Cambodia.
Trial registration number: NCT01663831
Funded by the Bill and Melinda Gates Foundation.
Risk of bias
Bias Authors’ judgement Support for judgement
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Sluydts 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Random sequence, calculation of restric-
tion factor, and validity matrix was car-
ried out in R using “onemillion random.
RData”
Allocation concealment (selection bias) Low risk All clusters were allocated a treatment at
start using a computer generated random
sequence
Blinding of participants and personnel
(performance bias)
Parasitaemia
High risk There was no placebo given to control
group.
Blinding of participants and personnel
(performance bias)
Clinical malaria
High risk There was no placebo given to control
group.
Blinding of participants and personnel
(performance bias)
Compliance
High risk There was no placebo given to control
group so it is unclear how compliance
might have been affected. Control group
was given LLIN and intervention group
was given a topical repellent in addition to
the LLIN. It is possible that participants
felt they would be protected by the repel-
lent and so would choose not to use their
bed net
Blinding of participants and personnel
(performance bias)
Adverse events
High risk There was no placebo given to control so
those given repellent lotionsmight have felt
more likely to suffer adverse effects
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Parasitaemia was measured by PCR which
is an objective test.
Blinding of outcome assessment (detection
bias)
Compliance
Unclear risk Compliance was only measured in the
treatment arm because there was no
placebo
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Adverse effectswere self-reported and could
have been influenced by the participant
knowing that he/she had been given a fully
effective mosquito repellent
Blinding of outcome assessment (detection
bias)
Clinical malaria
Unclear risk The trial was not placebo-controlled: in-
dividuals that received the repellent could
havementioned this tomedical staff and in-
fluenced their diagnosis of clinical malaria
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Sluydts 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was similar between groups.
Selective reporting (reporting bias) Low risk Reporting was done according to protocol.
Other bias Low risk Baseline imbalance.
Restrained randomization controlled for
baseline imbalances
Soto 1995
Methods RCT
Duration of the trial: 3 to 5 weeks followed by 4 weeks’ follow-up
Participants Colombian Army members stationed in endemic areas
Interventions Insecticide treated clothing versus placebo
Treatment arms:
- ITC 86 individuals;
- Placebo 86 individuals.
Outcomes - Participants with clinical malaria confirmed through blood smears or rapid diagnostic
tests (P. falciparum or P. vivax); and
- Recorded adverse events.
Notes Trial was conducted in the Colombian Amazon.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The randomization process is not de-
scribed.
Quote “troops were randomly assigned to
receive either permethrin-impregnated or
non-impregnated uniforms”
Allocation concealment (selection bias) Unclear risk Poorly described.
Blinding of participants and personnel
(performance bias)
Clinical malaria
Low risk Medical attendants and soldiers were
blinded to the intervention
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Medical attendants and soldiers were
blinded to the intervention
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Soto 1995 (Continued)
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Medical attendants and soldiers were
blinded to the intervention
Blinding of outcome assessment (detection
bias)
Clinical malaria
Low risk Medical attendants and soldiers were
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the study and there
were no losses to follow-up, no treatment
withdrawals, no trial group changes and no
major adverse events
Adherence to instructions (wearing
clothes) was not monitored so not possible
to assess whether soldiers were compliant
Selective reporting (reporting bias) Unclear risk Protocol not available and the correspond-
ing author failed to communicate
Other bias Unclear risk Baseline imbalance
Both study arms recruited similar num-
ber of soldiers and deployed them to the
same endemic area. However, the number
of weeks soldiers in each study arm were
deployed in the field was not reported per
arm
“Each soldier was in the area of endemicity
for 3-8 weeks.”
Syafruddin 2014
Methods Matched pair cluster-RCT, with the matching done according to village
Unit of randomization: cluster
ICC not reported.
Trial duration: 6 months
Participants Male adults between 18 and 60 years old, residents of malaria-endemic regions
Participants were screened at start and parasites were cleared
Interventions Mosquito coils (0.00975% metofluthrin) versus Placebo coils
No co-interventions
Treatment arms:
- Metofluthrin treated coils: 2 clusters with total of 216 households, population of 1001
individuals and 83 participants (males 18 to 60 years old) enrolled for follow-up;
- Placebo coils: 2 clusters with total of 229 households, population of 1119 and 87
participants (males 18 to 60 years old) enrolled for follow-up
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Syafruddin 2014 (Continued)
Outcomes - Participants with Plasmodium spp. parasitaemia confirmed through blood smear.
- Reduction in mosquito landings measured through human landing catch
- Adverse events.
Notes Trial was conducted in Umbugendo and Wainyapu in Southwest Sumba District, East
Nusa Tenggara Province, Indonesia
Funded by Bill and Melinda Gates Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization method was not described.
Allocation concealment (selection bias) Low risk The trial as a matched pair cRCT with
matching done according to village level.
There were only two clusters in each village:
therefore after treatment was allocated to
one cluster, it was obvious which treatment
would be allocated to the next cluster
Blinding of participants and personnel
(performance bias)
Parasitaemia
Low risk Blinding of both participants and person-
nel was in place.
“The study administrator obtained a list
of lot manufacturing codes from the coil
manufacturer (S.C. Johnson Co., Ho Chi
Minh, Vietnam) that identified coils as
either active or placebo. The administra-
tor then assigned a code specific to each
home and labelled packages of coils corre-
sponding to cluster assignment to active or
placebo coil treatment. These assignments
were kept in a sealed envelope in a secure
location within the managing centre of the
research program (Jakarta). Thus, the in-
vestigators, research team, study subjects,
and residents were blinded as towhich clus-
ter received active versus placebo coils until
after completion of the study.”
Blinding of participants and personnel
(performance bias)
Reduction in mosquitoes attempting to
feed on humans
Low risk Technicians collecting themosquitoes were
blinded to the interventions
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Blinding of both participants and person-
nel was in place.
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Syafruddin 2014 (Continued)
Blinding of outcome assessment (detection
bias)
Parasitaemia
Low risk Blinding of both participants and person-
nel was in place.
Diagnosis was done throughmicroscopy of
blood smear. Themethodwas not validated
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Blinding of both participants and person-
nel was in place.
Blinding of outcome assessment (detection
bias)
Reduction in mosquitoes attempting to
feed on humans
Low risk Blinding of both participants and person-
nel was in place.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals were reported.
Selective reporting (reporting bias) Low risk The primary outcomes set out by the au-
thor in the registered protocol match those
reported in the paper
Other bias Low risk Baseline imbalance
Study arms had similar baseline character-
istics.
Abbreviations: RCT: randomized controlled trial.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdulsalam 2014 The study only had two units of randomization.
Dadzie 2013 The study was not a randomized controlled trial (RCT).
Deressa 2014 The study did not specify the repellent compound tested.
Eamsila 1994 The study was not a RCT.
Hamza 2016 The study only had two units of randomization.
Kimani 2006 The study only had two units of randomization.
Abbreviations: RCT: randomized controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12616001434482
Trial name or title Effectiveness of mosquito repellent delivered through village health volunteers on malaria incidence in
artemisinin resistance containment programs in South-East Myanmar
Methods Open stepped-wedge cluster-randomized controlled trial (RCT)
Participants Men and women of all ages residing in the study area. High-risk populations (mobile and migrant people
and residents who are also forest dwellers) will be targeted to receive the repellent
Interventions 12% DEET cream versus no treatment
Outcomes The primary epidemiological outcomes will be incidence of Plasmodium spp. infection (diagnosed by an
mRDT) and incidence of malaria illness
Starting date 01-04-2015
Contact information Freya Fowkes (freya.fowkes@burnet.edu.au)
Notes www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001434482
NCT02294188
Trial name or title Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia
Methods Cluster-RCT
Participants Residents of malaria-endemic regions of Indonesia
Interventions Spatial repellent passive emanators versus placebo
Outcomes The primary epidemiological endpoint will be the incidence density of first time malaria infections among
human cohorts during the follow-up period as detected by polymerase chain reaction assay (PCR)
Starting date May 2015
Contact information Neil Lobo (nlobo@nd.edu)
Notes clinicaltrials.gov/ct2/show/NCT02294188
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NCT02653898
Trial name or title Malaria Elimination Pilot Study in Military Forces in Cambodia
Methods Cluster-RCT
Participants Residents of military encampments on the Thai-Cambodian border
Interventions Focused screening and treatment, malaria prophylaxis and insecticide-treated uniforms versus untreated uni-
forms
Outcomes The primary epidemiological outcome will be the absolute risk reduction based on the proportion of subjects
remaining malaria-free at the end of 6 months between the study arms as diagnosed by PCR-corrected malaria
microscopy
Starting date January 2016
Contact information Chanthap Lon (chantapl@afrims.org)
Notes clinicaltrials.gov/ct2/show/record/NCT02653898
NCT02938975
Trial name or title Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents for Malaria Prevention (URCT)
Methods Cluster-RCT using a 4-arm non-inferiority design with 12 months of follow-up
Participants Healthy recruits of the Tanzanian National Service Program JKT Mgambo Camp
Interventions Ultra 30 insect repellent lotion (30% Lipo DEET) in combination or not with permethrin factory-treated
army combat uniforms
Outcomes The primary epidemiological outcome will be the incidence of P. falciparum malaria through monthly mea-
surement of malaria positivity by direct polymerase chain reaction (PCR) to detect parasite DNA
Starting date November 2017
Contact information Sarah Moore (smoore@ihi.or.tz)
Notes clinicaltrials.gov/ct2/show/record/NCT02938975
Abbreviations: RCT: randomized controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Topical repellent compared to placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical malaria caused by
Plasmodium falciparum
3 4447 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.40, 1.07]
1.1 Without LLINs 1 869 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.23, 0.71]
1.2 With LLINS 2 3578 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.55, 1.27]
2 Plasmodium falciparum
parasitaemia
4 13310 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.64, 1.12]
2.1 Without LLINs 1 897 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.53, 1.16]
2.2 With LLINs 3 12413 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.60, 1.38]
3 Clinical malaria caused by
Plasmodium vivax
2 3996 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.99, 1.76]
3.1 Without LLINs 1 869 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.02, 1.99]
3.2 With LLINs 1 3127 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.64, 1.94]
4 Plasmodium vivax parasitaemia 3 9589 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.81, 1.43]
4.1 Without LLINs 1 897 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.68, 1.40]
4.2 With LLINs 2 8692 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.78, 1.97]
5 Anaemia 1 587 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.23]
6 All-cause fever 1 3496 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.35, 0.55]
7 Adherence to the intervention Other data No numeric data
8 Adverse events Other data No numeric data
Comparison 2. ITC compared to placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical malaria caused by
Plasmodium falciparum
2 Risk Ratio (Fixed, 95% CI) 0.49 [0.29, 0.83]
2 Clinical malaria caused by
Plasmodium vivax
2 Risk Ratio (Fixed, 95% CI) 0.64 [0.40, 1.01]
3 Adverse events Other data No numeric data
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Comparison 3. Spatial repellents compared to placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Plasmodium spp. parasitaemia 2 Risk Ratio (Random, 95% CI) 0.24 [0.03, 1.72]
2 Adherence to the intervention Other data No numeric data
3 Reduction in mosquito bites 1 16 Mean Difference (IV, Fixed, 95% CI) -10.8 [-16.23, -5.37]
4 Adverse events Other data No numeric data
Analysis 1.1. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 1 Clinical
malaria caused by Plasmodium falciparum.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 1 Clinical malaria caused by Plasmodium falciparum
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Without LLINs
Rowland 2004 17/468 36/401 35.1 % 0.40 [ 0.23, 0.71 ]
Subtotal (95% CI) 468 401 35.1 % 0.40 [ 0.23, 0.71 ]
Total events: 17 (Topical Repellents), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
2 With LLINS
Sluydts 2016 29/1604 33/1523 39.0 % 0.83 [ 0.51, 1.37 ]
Sangoro 2014a 12/227 14/224 25.9 % 0.85 [ 0.40, 1.79 ]
Subtotal (95% CI) 1831 1747 64.9 % 0.84 [ 0.55, 1.27 ]
Total events: 41 (Topical Repellents), 47 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 2299 2148 100.0 % 0.65 [ 0.40, 1.07 ]
Total events: 58 (Topical Repellents), 83 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.20, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Chi2 = 4.20, df = 1 (P = 0.04), I2 =76%
0.01 0.1 1 10 100
Favour topical repellents Favours control
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Analysis 1.2. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 2
Plasmodium falciparum parasitaemia.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 2 Plasmodium falciparum parasitaemia
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Without LLINs
McGready 2001 40/449 51/448 52.0 % 0.78 [ 0.53, 1.16 ]
Subtotal (95% CI) 449 448 52.0 % 0.78 [ 0.53, 1.16 ]
Total events: 40 (Topical Repellents), 51 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 With LLINs
Chen-Hussey 2013 30/3408 28/3420 28.5 % 1.08 [ 0.64, 1.80 ]
Hill 2007 1/1780 5/1716 5.2 % 0.19 [ 0.02, 1.65 ]
Sluydts 2016 12/1050 14/1039 14.3 % 0.85 [ 0.39, 1.82 ]
Subtotal (95% CI) 6238 6175 48.0 % 0.91 [ 0.60, 1.38 ]
Total events: 43 (Topical Repellents), 47 (Control)
Heterogeneity: Chi2 = 2.44, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 6687 6623 100.0 % 0.84 [ 0.64, 1.12 ]
Total events: 83 (Topical Repellents), 98 (Control)
Heterogeneity: Chi2 = 2.82, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favour topical repellents Favours control
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Analysis 1.3. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 3 Clinical
malaria caused by Plasmodium vivax.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 3 Clinical malaria caused by Plasmodium vivax
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Without LLINs
Rowland 2004 78/468 47/401 68.2 % 1.42 [ 1.02, 1.99 ]
Subtotal (95% CI) 468 401 68.2 % 1.42 [ 1.02, 1.99 ]
Total events: 78 (Topical Repellents), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
2 With LLINs
Sluydts 2016 27/1604 23/1523 31.8 % 1.11 [ 0.64, 1.94 ]
Subtotal (95% CI) 1604 1523 31.8 % 1.11 [ 0.64, 1.94 ]
Total events: 27 (Topical Repellents), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 2072 1924 100.0 % 1.32 [ 0.99, 1.76 ]
Total events: 105 (Topical Repellents), 70 (Control)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favour topical repellents Favours control
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Analysis 1.4. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 4
Plasmodium vivax parasitaemia.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 4 Plasmodium vivax parasitaemia
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Without LLINs
McGready 2001 52/449 53/448 62.3 % 0.98 [ 0.68, 1.40 ]
Subtotal (95% CI) 449 448 62.3 % 0.98 [ 0.68, 1.40 ]
Total events: 52 (Topical Repellents), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 With LLINs
Chen-Hussey 2013 12/3296 13/3307 15.2 % 0.93 [ 0.42, 2.03 ]
Sluydts 2016 28/1050 19/1039 22.4 % 1.46 [ 0.82, 2.59 ]
Subtotal (95% CI) 4346 4346 37.7 % 1.24 [ 0.78, 1.97 ]
Total events: 40 (Topical Repellents), 32 (Control)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 4795 4794 100.0 % 1.08 [ 0.81, 1.43 ]
Total events: 92 (Topical Repellents), 85 (Control)
Heterogeneity: Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
Favour topical repellents Favours control
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Analysis 1.5. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 5 Anaemia.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 5 Anaemia
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McGready 2001 161/293 153/294 100.0 % 1.06 [ 0.91, 1.23 ]
Total (95% CI) 293 294 100.0 % 1.06 [ 0.91, 1.23 ]
Total events: 161 (Topical Repellents), 153 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical repellents Favours control
Analysis 1.6. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 6 All-cause
fever.
Review: Mosquito repellents for malaria prevention
Comparison: 1 Topical repellent compared to placebo or no treatment
Outcome: 6 All-cause fever
Study or subgroup Topical Repellents Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hill 2007 99/1716 236/1780 100.0 % 0.44 [ 0.35, 0.55 ]
Total (95% CI) 1716 1780 100.0 % 0.44 [ 0.35, 0.55 ]
Total events: 99 (Topical Repellents), 236 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.24 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical repellents Favours control
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Analysis 1.7. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 7 Adherence
to the intervention.
Adherence to the intervention
Study Follow up length Method Compliance repellent arm Compliance treatment
arm
Chen-Hussey 2013 Monthly Self reporting
Estimating weight of repel-
lent bottles.
61.3% 62.2%
Hill 2007 Monthly Self reporting
Random unanounced “sniff
check”
Estimating weight of repel-
lent bottles.
98.5% 98.5%
McGready 2001 Weekly Self reporting
Random spot checks
Unclear Unclear
Sangoro 2014a Monthly Self reporting
Mean number of bottles is-
sued to each household
Unclear Unclear
Sluydts 2016 Non-periodic Self reporting
Observational studies
Unclear Unclear
Analysis 1.8. Comparison 1 Topical repellent compared to placebo or no treatment, Outcome 8 Adverse
events.
Adverse events
Study Follow up
length
Method Unit Description of
adverse events
Intervention
arm
Control arm
Hill 2007 Monthly surveys Interview Even per house-
hold
None reported 0/424 0/436
McGready 2001 Weekly surveys Interview Unclear 6% of the partic-
ipants
reported skin
warming sensa-
tion.
Unclear Unclear
Rowland 2004 End of trial Interviews and
questionnaires to
20 households
from each treat-
ment arm
Event per house-
hold
Skin irritation 1/20 0/20
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Adverse events (Continued)
Sluydts 2016 Unclear Unclear Unclear Not described 41/unclear
Analysis 2.1. Comparison 2 ITC compared to placebo or no treatment, Outcome 1 Clinical malaria caused
by Plasmodium falciparum.
Review: Mosquito repellents for malaria prevention
Comparison: 2 ITC compared to placebo or no treatment
Outcome: 1 Clinical malaria caused by Plasmodium falciparum
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Soto 1995 -1.9812 (1.5196) 3.1 % 0.14 [ 0.01, 2.71 ]
Rowland 1999 -0.6733 (0.2707) 96.9 % 0.51 [ 0.30, 0.87 ]
Total (95% CI) 100.0 % 0.49 [ 0.29, 0.83 ]
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours ITC Favours control
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Analysis 2.2. Comparison 2 ITC compared to placebo or no treatment, Outcome 2 Clinical malaria caused
by Plasmodium vivax.
Review: Mosquito repellents for malaria prevention
Comparison: 2 ITC compared to placebo or no treatment
Outcome: 2 Clinical malaria caused by Plasmodium vivax
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Soto 1995 -1.1736 (0.6852) 11.6 % 0.31 [ 0.08, 1.18 ]
Rowland 1999 -0.3567 (0.2486) 88.4 % 0.70 [ 0.43, 1.14 ]
Total (95% CI) 100.0 % 0.64 [ 0.40, 1.01 ]
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ITC Favours control
Analysis 2.3. Comparison 2 ITC compared to placebo or no treatment, Outcome 3 Adverse events.
Adverse events
Study Follow up
length
Method Unit Description of
adverse events
Intervention arm Control arm
Rowland 1999 16 weeks Interview Event per house-
hold
None reported 0/438 0/387
Soto 1995 End of trial Interview Event per partici-
pant
Skin irritation 2/229 0/229
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Analysis 3.1. Comparison 3 Spatial repellents compared to placebo or no treatment, Outcome 1
Plasmodium spp. parasitaemia.
Review: Mosquito repellents for malaria prevention
Comparison: 3 Spatial repellents compared to placebo or no treatment
Outcome: 1 Plasmodium spp. parasitaemia
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Hill 2014 -2.4218 (1.0442) 49.3 % 0.09 [ 0.01, 0.69 ]
Syafruddin 2014 -0.4283 (1.0191) 50.7 % 0.65 [ 0.09, 4.80 ]
Total (95% CI) 100.0 % 0.24 [ 0.03, 1.72 ]
Heterogeneity: Tau2 = 0.92; Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours spatial repellent Favours control
Analysis 3.2. Comparison 3 Spatial repellents compared to placebo or no treatment, Outcome 2
Adherence to the intervention.
Adherence to the intervention
Study Follow up length Method Compliance control arms Compliance treatment arms
Hill 2014 monthly survey Self reporting
Counting of empty coil boxes
No treatment arm: 89.3%
LLINs only arm: 97.8%
Repellent coils arm: 98.6%
Repellent coils + LLINs arm:
98.5%
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Analysis 3.3. Comparison 3 Spatial repellents compared to placebo or no treatment, Outcome 3 Reduction
in mosquito bites.
Review: Mosquito repellents for malaria prevention
Comparison: 3 Spatial repellents compared to placebo or no treatment
Outcome: 3 Reduction in mosquito bites
Study or subgroup Spatial repellents Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hill 2014 8 2.1 (1.9) 8 12.9 (7.6) 100.0 % -10.80 [ -16.23, -5.37 ]
Total (95% CI) 8 8 100.0 % -10.80 [ -16.23, -5.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.90 (P = 0.000096)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours spatial repellent Favours control
Analysis 3.4. Comparison 3 Spatial repellents compared to placebo or no treatment, Outcome 4 Adverse
events.
Adverse events
Study Follow-up
length
Method Unit Description of
adverse events
Intervention arm Control arm
Syafruddin 2014 6 months Interviews Random spot-
checks
None described None reported None reported
A D D I T I O N A L T A B L E S
Table 1. Assessment of compliance
Study Intervention
group
Design Method of
assessing com-
pliance
Unit Follow-up
time
Compliance level1
Intervention
arm
Placebo arm
Chen-Hussey
2013
Topical repel-
lent
cRCT Self-reported
compliance.
Self-reported
combined with
an estimationof
the proportion
Per-
centage of self-
reported partic-
ipants/night
that adhered to
the assigned
Monthly
surveys
Moderate: 61.
3%
Moderate: 62.
2%
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Table 1. Assessment of compliance (Continued)
of lotion used
by the partici-
pant by weigh-
ing the returned
bottles
treatment in a
given month
Partic-
ipants who re-
ported to have
used the repel-
lent and con-
firmed by the
weight of re-
turned bottles
Hill 2007 Topical repel-
lent
cRCT Self-
reported com-
pliance through
questionnaires
combined with
an estimationof
the amount
used by weigh-
ing the returned
bottles, and ver-
ified by unan-
nounced “sniff
checks”
Cumu-
lative percent-
age of compli-
ant households
per month.
A household
was considered
non-com-
pliant if they
had reported to
have not used
the repellent 3
or more nights
in a month or
had more than
30 ml left in the
bottle
Monthly
surveys
High: 98.5%
(119/8164)
High: 98.5%
(110/7876)
Hill 2014 Spatial repel-
lent
cRCT Daily record-
ings of compli-
ance per house-
hold were re-
ported by vil-
lage
leaders. Com-
pliance was fur-
ther confirmed
by counting the
num-
ber of empty
mosquito coil
boxes in each
house
Cumu-
lative percent-
age of compli-
ant households
per month.
A household
was considered
non-compli-
ant if it did not
use the coils for
3 days or longer
in one month
Monthly
surveys
High
No treatment
arm: 89.3%
LLIN arm: 97.
8%
High
Repellent coils
arm: 98.6%
Repellent coils
+ LLINs: 98.
5%
McGready
2001
Topical repel-
lent
RCT Weekly self-re-
port-
ing and random
spot checks.
Cumu-
lative percent-
age of compli-
ant participants
per week.
Weekly surveys Unclear
Compliance was reported to be
similar across treatment arms (P
= 0.24) but was not reported for
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Table 1. Assessment of compliance (Continued)
each arm
Self-reported compliance: 90.5%
(87,715/96,955)
Compliance measured by spot
checks: 84.6% (1918/2267)
Sangoro
2014a
Topical repel-
lent
cRCT Self-
reported com-
pliance through
questionnaires
combined with
an estimationof
the amount
used by count-
ing the empty
returned bottles
Mean number
of bottles of re-
pellent issued to
each household
per month
Monthly
surveys
Unclear
Authors stated that self-reported
data was unreliable so they used
the data from the empty bottles to
estimate compliance. Compliance
was poorly reported. The authors
reported mean number of bottles
issued per household per month
rather than estimating the compli-
ance level for each treatment arm:
Repellent arm: 6.73 bottles (95%
CI 6.51 to 6.95)
Placebo arm: 6.92bottles (95%CI
6.68 to 7.16)
Sluydts 2016 Topical repel-
lent
cRCT Self-reported
compliance was
assessed
using question-
naires during 3
sur-
veys in October
2012, March
2013 andOcto-
ber 2013
The repellent
consumption
rate was mea-
sured per family
every 2 weeks
during the re-
pellent dis-
tribution by vi-
sual inspection
of the leftover
repellent di-
vided into cat-
egories (for ex-
ample, empty,
half full, full)
A social science
study was done
Unit of mea-
surement
was not clearly
defined.
Self-re-
ported compli-
ance is likely the
percent-
age of compli-
ant households
during the sur-
vey period but
was not defined
in the article
The repel-
lent consump-
tion rate was
not reported.
Social study re-
ported percent-
age of partici-
pants observed
to comply with
the application
of the repellent
from a small se-
lec-
Non-peri-
odic surveys (in
October 2012,
March
2013 andOcto-
ber 2013) along
the duration of
the trial
Self-
reported com-
pliance was re-
ported around
70%.
However,
observational
studies reported
compliance be-
tween 6% and
15%
No placebo
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Table 1. Assessment of compliance (Continued)
to assess the ac-
ceptability and
use of repellents
in 10 selected
clusters
tion of 10 clus-
ters in the inter-
vention group
1Levels of compliance: high: > 80%; moderate: 50% to 79%; low: < 50%.
Table 2. Epidemiology of malaria and major vector of the study region
Study Intervention Design Transmission
intensity1,2
Region Main malaria
vectors
Biting times Efficacy of the
intervention at
repelling
Anophelines
tested at base-
line? (V/N)
Chen-Hussey
2013
Topical repel-
lent
cRCT Hypoendemic
0.83% P. falci-
parum
0.4% P. vivax
Measured
through active
case detection
South East Asia
- Laos
Anopheles dirus
An. minimus
An. maculatus
From 18:00 to
2:00 with peak
biting time
from 21.00 to
02.00
No
Hill 2007 Topical repel-
lent
cRCT Hypoendemic
0.31% P. falci-
parum
Measured
through active
case detection
South America:
Bolivian Ama-
zon Region
An. darlingi Peak biting ac-
tivity between 8
p.m. and 10 p.
m.
Yes
Moore 2002
Hill 2014 Spatial repel-
lent
cRCT Hypoendemic
0.06% P. falci-
parum
0.28% P. vivax
Measured
through active
case detection
South
East Asia: Yun-
nan Province of
China
An. sinensis
An. minimus
An. kochi
An. splendidus
An barbirostris
An. vagus
An. jeyporiensis
An. annularis
An. philippinsis
An. tessallatus
An. maculatus
An. barbumbro-
sus
An. dirus
An culicifacies
Given the di-
ver-
sity of vectors in
the area the bit-
ing activity oc-
curs from early
evening extend-
ing to later in
the night
Yes
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Table 2. Epidemiology of malaria and major vector of the study region (Continued)
McGready
2001
Topical repel-
lent
RCT Mesoendemic
11.4% P. falci-
parum
11.8% P. vivax
Measured
through active
case detection
South East
Asia: Thailand
Not reported Not reported No
Rowland
1999
Insecticide
treated cloth-
ing
cRCT Holoendemic
20.7% P. falci-
parum
17.6% P. vivax
Measured
through passive
case detection
North Western
Pakistan
An. nigerrimus
An. subpictus
An. stephensi
Not reported Yes
Rowland
2004
Topical repel-
lent
cRCT Mesoendemic
8.9% P. falci-
parum
11.7% P. vivax
Measured
through passive
case detection
Asia: Pakistan An. culicifacies
An. stephensi
An. nigerrimus
An.
pulcherrimus
Mosquito bit-
ing starts af-
ter dusk, peaks
around 9 p.m.
to 11 p.m. then
declines gradu-
ally through the
night
Yes
Sangoro
2014a
Topical repel-
lent
cRCT Mesoendemic
6.22% P. falci-
parum
Measured
through passive
case detection
East Africa:
Tanzania
An gambiae s.s.
An arabiensis
Biting activ-
ity starts early
evening and
continues into
the later hours
of the night
Yes
Sangoro 2014c
Sluydts 2016 Topical repel-
lent
cRCT Hypoendemic
1.33% P. falci-
parum
1.85% P. vivax
Measured
through active
case detection
Southeast Asia:
Cambodia
An. dirus s.s.
An. maculatus
An barbirostris
An.minimus s.s.
An. sawadwong-
porni
An aconitus
Early evening
biting was com-
mon.
Yes
Van Roey 2014
Soto 1995 Insecticide-
treated cloth-
ing
RCT Mesoen-
demic for P.vi-
vax and Hy-
poenemic for P.
falciparum
3.4% P. falci-
parum
10.4% P. vivax
Measured
South America:
Colombia
Unclear Not reported No
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Table 2. Epidemiology of malaria and major vector of the study region (Continued)
through passive
case detection
Syafruddin
2014
Spatial repel-
lent
cRCT Holoendemic
for Plasmodium
spp.
70.1% Plas-
modium spp.
Measured
through passive
case detection
Asia:
Indonesia
An. sundaicus
An. subpictus s.l.
An. indefinitus
An. vagus
An. barbirostris
An. annularis
An. maculatus
An. aconitus
An. kochi
An. tessellatus
Early evening
biting was com-
mon with peaks
between 18:00
and 20:00 con-
tinu-
ing throughout
the night. The
high diversity of
vectors also re-
flected diverse
biting patterns
Yes
Barbara 2011
1Transmission intensity: holo-endemic: malaria prevalence > 15%; meso-endemic: malaria prevalence 5% to 15%; and hypo-endemic:
malaria prevalence < 5%.
2Calculated from prevalence in the control group.
Table 3. Malaria diagnostic methods
Study Intervention Design Diagnostic
method
Validated Plasmod-
ium species in the
region
Par-
ticipants screened
and cleared for vi-
vax (Y/N)
Chen-Hussey
2013
Topical repellent cRCT mRDT Yes, by PCR 80% P. falciparum
20% P. vivax
No
Hill 2007 Topical repellent cRCT mRDT No P. falciparum
P. vivax
No1
Hill 2014 Spatial repellent cRCT mRDTs Yes, positive RDTs
were
validated through
thick blood slide.
32% P. falciparum
58% P. vivax
Yes
McGready 2001 Topical repellent RCT Blood smear No P. falciparum
P. vivax
No
Rowland 1999 Insecticide-
treated clothing
cRCT Blood smear No P. falciparum
P. vivax
No
Rowland 2004 Topical repellent cRCT Blood smear No P. falciparum
P. vivax
No
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Table 3. Malaria diagnostic methods (Continued)
Sangoro 2014a Topical repellent cRCT mRDT Unclear
if microscopy was
used for validation
of positive mRDTs
Mainly P.
falciparum
No1
Sluydts 2016 Topical repellent cRCT PCR No P. falciparum
P. vivax
No
Soto 1995 Insecticide-
treated clothing
RCT Blood smear No P. falciparum
P. vivax
No
Syafruddin 2014 Spatial repellent cRCT Blood smear No P. falciparum
P. vivax
Yes
1mRDT was only specific for P. falciparum.
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (PubMed)
Search Query
#21 Search (#20) AND #17
#20 Search (#19) OR #18
#19 Search “Randomised Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
#18 Search randomised OR placebo OR randomly OR groups OR trial Field: Title/Abstract
#17 Search (#16) AND #8
#16 Search ((((((#9) OR #10) OR #11) OR #12) OR #13) OR #14) OR #15)
#15 Search “vaporizer mat*” Field: Title/Abstract
#14 Search “personal protection*” Field: Title/Abstract
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(Continued)
#13 Search “impregnated cloth*” Field: Title/Abstract
#12 Search “electric emanator*” Field: Title/Abstract
#11 Search Spray OR sprays OR lotion* OR gel OR gels OR roll-on* OR wipe* Field: Title/Abstract
#10 Search “insecticide treated clothing” OR ITC Field: Title/Abstract
#9 Search repellen* Field: Title/Abstract
#8 Search ((#5) OR #6) OR #7
#7 Search “Anopheles”[Mesh]
#6 Search “Mosquito Control”[Mesh]
#5 Search (#4) AND #1
#4 Search (#2) OR #3
#3 Search (“Insect Vectors”[Mesh])
#2 Search vector* OR mosquito* Field: Title/Abstract
#1 Search malaria Field: Title/Abstract
Cochrane Library
#1 “malaria”:ti,ab,kw (Word variations have been searched)
#2 vector* or mosquito*:ti,ab,kw (Word variations have been searched)
#3 MeSH descriptor: [Insect Vectors] explode all trees
#4 MeSH descriptor: [Anopheles] explode all trees
#5 #2 or #3 or #4
#6 #1 and #5
#7 MeSH descriptor: [Mosquito Control] explode all trees
#8 #6 or #7
#9 Spray or sprays or lotion* or gel or gels or roll-on* or wipe* or repellen* or coil*:ti,ab,kw
#10 “insecticide treated clothing” or ITC:ti,ab,kw
#11 “passive emanator*” ti,ab,kw
#12 “electric emanator*” ti,ab,kw
#13 “vaporizer mat*” ti,ab,kw
#14 “personal protection” ti,ab,kw
#15 #9 or #10 or #11 or #12 or #13 or or #14
#16 #8 and #15
Embase (OVID)
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Results Search Type
1 malaria.mp. or malaria/
2 insect vectors.mp. or disease carrier/
3 mosquito/ or mosquito.mp.
4 Anopheles/
5 2 or 3 or 4
6 1 and 5
7 mosquito control.mp.
8 6 or 7
9 insect repellent/ or insecticide treated clothing.mp.
10 (coil* or spray or sprays or lotion* or gel or gels or roll-on* or wipe*).ab. or (coil* or spray or sprays or lotion* or gel or
gels or roll-on* or wipe*).ti
11 passive emanator*.ab. or passive emanator*.ti.
12 electric emanator*.ab. or electric emanator*.ti.
13 vaporizer mat*.ab. or vaporizer mat*.ti.
14 personal protection.ab. or personal protection.ti.
15 9 or 10 or 11 or 12 or 13 or 14
16 8 and 15
17 clinical trial/
18 randomised controlled trial/
19 17 or 18
20 randomisation/
21 (single blind* or double blind*).mp.
22 random allocation.mp.
23 randomly allocated.mp.
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(Continued)
24 cluster randomised.mp.
25 17 or 18 or 20 or 21 or 22 or 23 or 24
26 16 and 25
CABI: CAB Abstracts®
# 5 #4 AND #3
Timespan=All years
Search language=Auto
# 4 TOPIC: (randomised OR double-blind* or single-blind*OR placebo OR randomly)
Timespan=All years
Search language=Auto
# 3 #2 AND #1
Timespan=All years
Search language=Auto
# 2 TOPIC: (Spray or sprays or lotion* or gel or gels or roll-on* or wipe* O repellen* or coil*) OR TOPIC: (insecticide treated
clothing) OR TOPIC: (vaporizer mat*) OR TOPIC: (personal protection)
Timespan=All years
Search language=Auto
# 1 TOPIC: (malaria) AND TOPIC: (vector* OR mosquito* OR anopheles)
Timespan=All years
Search language=Auto
LILACS
Database : LILACS
Search on : malaria and (mosquito$ or vector$) [Words] and repellent$ or spray$ or coils or emanator$ or vaporizer$ or clothing
[Words] and randomised or trial or controlled or placebo [Words]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
With regard to P. vivax infections, we had originally described in the protocol that data onP. vivax from studies that had not cleared
parasites at start would be excluded. However only two of the included studies, which both focused on spatial repellents, cleared
parasites at start. If a study undertook a proper randomization, recrudescent infections would be similar between treatment arms. For
this reason we decided to include data on P. vivax regardless of whether infections had been cleared at start or not.
We also decided to subgroup by use or not of LLINs as a co-intervention rather than by endemicity level, compliance and diagnostic
methods, as described in the protocol. This was done because we believe there was heterogeneity between studies that included and did
not include LLINs as co-interventions. Also, given that current malaria control programmes all incorporate LLINs, we believe policy
makers are mostly interested in the combined effect of LLINs with topical repellents rather than these on their own.
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